Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             967 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Abnormalities in the circadian rhythm of parathyroid hormone and serum bone markers in adults with growth hormone deficiency Hopkins, M.T.
 1999
 72-73 S1 p. 162-
1 p.
 artikel
2 Acromegaly and colon cancer Jenkins, Paul J.
 2000
 72-73 S1 p. S35-S36
2 p.
 artikel
3 Acromegaly and prostate cancer Colao, Annamaria
 2000
 72-73 S1 p. S37-S38
2 p.
 artikel
4 Activation of the hypothalamic-pituitary-adrenal axis in obesity: Cause or consequence? Walker, Brian R
 2001
 72-73 S1 p. S91-S95
5 p.
 artikel
5 Adiposity in adult growth hormone deficiency:prediction factor of growth hormone replacement dosage? Boquete, H.
 2001
 72-73 S1 p. S142-
1 p.
 artikel
6 Administration of growth hormone to catabolic patients Hinds, C.J.
 1999
 72-73 S1 p. 71-75
5 p.
 artikel
7 Adult growth hormone deficiencysyndrome: A personal approach to diagnosis, treatment and monitoring Cook, D.M.
 1999
 72-73 S1 p. 129-133
5 p.
 artikel
8 Adult vs childhood onset GHD: Is there a real clinical difference? van der Lely, A.J.
 1998
 72-73 S1 p. 21-23
3 p.
 artikel
9 A low growth hormone (GH) dose given to youngadults with childhood-onset GH deficiency increases kidney length Link, K.
 1999
 72-73 S1 p. 148-
1 p.
 artikel
10 A low growth hormone (GH) dose given to youngadults with childhood-onset GH deficiency increases left ventricular mass Link, K.
 1999
 72-73 S1 p. 146-
1 p.
 artikel
11 Antiproliferative and pro-apoptotic activities of insulin-like growth factor-binding protein-3 Baxter, Robert C.
 2000
 72-73 S1 p. S10-S11
2 p.
 artikel
12 Applications of new geneticapproaches to growth hormone-releasing hormone receptor defects Phillips, J.A.
 1999
 72-73 S1 p. 45-49
5 p.
 artikel
13 A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men Ma, Jing
 2000
 72-73 S1 p. S28-S29
2 p.
 artikel
14 Associate Editors 2014
 72-73 S1 p. i-
1 p.
 artikel
15 Association between hypopituitarism and otherchronic conditions — epilepsy, diabetes mellitus, coronary heart disease and psychiatric illness Lane, H.
 2001
 72-73 S1 p. S150-
1 p.
 artikel
16 A study of adults with Prader-Willi syndrome Höybye, C.
 1999
 72-73 S1 p. 163-
1 p.
 artikel
17 Author index 2010
 72-73 S1 p. S83-S87
5 p.
 artikel
18 Author index 2016
 72-73 S1 p. S50-S53
4 p.
 artikel
19 Author index 2008
 72-73 S1 p. S61-S65
5 p.
 artikel
20 Author index 2014
 72-73 S1 p. S53-S56
4 p.
 artikel
21 Author index 2012
 72-73 S1 p. S89-S94
6 p.
 artikel
22 Benefit of growth hormone (GH) in GH-deficient adults after long-term substitution: Are there parameters influencing response? Pavel, M.
 2001
 72-73 S1 p. S126-
1 p.
 artikel
23 Benefits of growth hormone treatment on bone metabolism, bone density and bone strength in growth hormone deficiency and osteoporosis Wüster, C.
 1998
 72-73 S1 p. 87-94
8 p.
 artikel
24 Body composition and glucose metabolism in patients with active and inactive acromegaly Herrmann, B.
 2001
 72-73 S1 p. S138-
1 p.
 artikel
25 Body composition and serum leptin levels inpatients with hypopituitarism Paramo, C.
 1999
 72-73 S1 p. 153-
1 p.
 artikel
26 Bone mineral density and parameters of bonemetabolism in patients with acromegaly Góth, M.I.
 2001
 72-73 S1 p. S137-
1 p.
 artikel
27 Cancer and the potential place for growth hormone receptor antagonist therapy Friend, Keith E.
 2001
 72-73 S1 p. S121-S123
3 p.
 artikel
28 Childhood onset of GH deficiency:Reassessment of GH status and effects of substitution Butenandt, O.
 1998
 72-73 S1 p. 9-13
5 p.
 artikel
29 Clinical implications of pulsatile hormone signals Hauffa, Berthold P.
 2001
 72-73 S1 p. S1-S8
8 p.
 artikel
30 Comparison of long-term growth in Japanese children on peritoneal dialysis with and without growth hormone therapy Wada, N.
 2001
 72-73 S1 p. S155-
1 p.
 artikel
31 Conflicts with the sornatopause Toogood, A.A.
 1998
 72-73 S1 p. 47-54
8 p.
 artikel
32 Consequences of stopping growthhormone (GH) therapy in young GH deficient patients with childhood onset disease Juul, A.
 1998
 72-73 S1 p. 15-19
5 p.
 artikel
33 Copyright 2014
 72-73 S1 p. vi-
1 p.
 artikel
34 Defects of the growth hormonereceptor and their clinical implications Savage, M.O.
 1999
 72-73 S1 p. 57-61
5 p.
 artikel
35 Dehydroepiandrosterone sulphate levels inpatients with hypopituitarism and severe growth hormone (GH) deficiency: Comparison with insulin-like growth factor I levels before and during GH replacement Aimaretti, G.
 1999
 72-73 S1 p. 141-
1 p.
 artikel
36 Detection of growth hormone gene defects bydideoxy fingerprinting Miyata, I.
 1999
 72-73 S1 p. 159-
1 p.
 artikel
37 Diagnosis of GH deficiency in adults Ghigo, E.
 1998
 72-73 S1 p. 55-58
4 p.
 artikel
38 Discontinuation of growth hormone treatmentin adolescent patients: Effects on metabolic parameters, quality of life and psychological well-being Johannsson, G.
 1999
 72-73 S1 p. 142-
1 p.
 artikel
39 DL The ubiquitin-proteolytic system: from bench to bedside Ciechanover, A.
 2008
 72-73 S1 p. S10-
1 p.
 artikel
40 Does growth hormone replacement therapy in adult growth hormone-deficient patients result in recurrence of, or increase in size of, pituitary tumours? Wright, J.E.
 2001
 72-73 S1 p. S139-
1 p.
 artikel
41 Does growth hormone therapy in adult patients with growth hormone deficiency protect against bone loss? Brixen, K.
 1998
 72-73 S1 p. 81-86
6 p.
 artikel
42 Do the right patients remain in growth hormone treatment — a six-year follow-up study of a growth hormone-deficient adult cohort Viikari, J.
 2001
 72-73 S1 p. S129-
1 p.
 artikel
43 Echocardiographic evaluation of cardiac function in transgenic mice over-expressing the bovine growth hormone gene Bohlooly-Y, M.
 1999
 72-73 S1 p. 156-
1 p.
 artikel
44 Editor Emeritus 2014
 72-73 S1 p. i-
1 p.
 artikel
45 Editorial Board 2010
 72-73 S1 p. i-
1 p.
 artikel
46 Editorial Board 2014
 72-73 S1 p. i-
1 p.
 artikel
47 Editorial Board 2008
 72-73 S1 p. i-
1 p.
 artikel
48 Editorial Board 2012
 72-73 S1 p. i-
1 p.
 artikel
49 Editor-in-Chief (Europe & RoW) 2014
 72-73 S1 p. i-
1 p.
 artikel
50 Editor-in-Chief (The Americas) 2014
 72-73 S1 p. i-
1 p.
 artikel
51 Effect of growth hormone (GH) replacementtherapy on the body composition of adults with GH deficiency Guisti, V.
 1999
 72-73 S1 p. 149-
1 p.
 artikel
52 Effect of growth hormone (GH) treatment on biochemical bone markers and bone mineral density in GH-deficient adults Bayraktar, F.
 1999
 72-73 S1 p. 161-
1 p.
 artikel
53 Effect of growth hormone treatment in an experimental model of focal glomerular sclerosis Fujimoto, M.
 1999
 72-73 S1 p. 157-
1 p.
 artikel
54 Effect of leptin on basal and follicle-stimulating hormone stimulated steroidogenesis in human granulosa cells Greisen, S.
 1999
 72-73 S1 p. 152-
1 p.
 artikel
55 Effect of 30 months of growth hormone (GH) replacement therapy on bone metabolism in adults with GH deficiency Kaldrymidis, P.H.
 1999
 72-73 S1 p. 161-
1 p.
 artikel
56 Effect of the liver proliferator cyproterone acetate on liver growth in interleukin-6-deficient mice Wallenius, V.
 1999
 72-73 S1 p. 155-
1 p.
 artikel
57 Effect of two weeks of growth hormonetreatment in burn patients on conservative management Dash, R.J.
 2001
 72-73 S1 p. S152-S153
2 p.
 artikel
58 Effects of growth hormone (GH) replacement therapy on quality of life in adults with GH deficiency Heberling, H.A.
 1999
 72-73 S1 p. 143-
1 p.
 artikel
59 Effects of growth hormone (GH) treatment onvery-low-density lipoprotein apolipoprotein 13100 turnover in GH deficient adults Chrisoulidou, A.
 1999
 72-73 S1 p. 145-
1 p.
 artikel
60 Effects of growth hormone on hepatic cholesterol metabolism. Lessons from studies in rats and humans Rudling, M.
 1999
 72-73 S1 p. 1-7
7 p.
 artikel
61 Effects of growth hormone replacement on cortisol metabolism in hypopituitary patients treated with cortisone acetate Beentjes, J.A.M.
 2001
 72-73 S1 p. S134-
1 p.
 artikel
62 Effects of reduction of free fatty acids ongrowth hormone (GH)-releasing hormone-stimulated GH release in adults after pituitary surgery van Dam, P.S.
 2001
 72-73 S1 p. S125-
1 p.
 artikel
63 Effects of 7 years of growth hormone (GH)therapy in GH-deficient adults with insulin sensitivity Svensson, J.
 2001
 72-73 S1 p. S130-
1 p.
 artikel
64 Endocrine changes in criticallyill patients Van den Berghe, G.
 1999
 72-73 S1 p. 77-81
5 p.
 artikel
65 Experience with pegvisomant in the treatment of acromegaly Drake, William M.
 2001
 72-73 S1 p. S111-S114
4 p.
 artikel
66 Findings and theoretical considerations on the usefulness of the acid-labile subunit in the monitoring of acromegaly Morrison, Katherine M.
 2001
 72-73 S1 p. S61-S63
3 p.
 artikel
67 First International Workshop on Growth Hormone, Insulin-like Growth Factors and Neoplasia Pollak, Michael
 2000
 72-73 S1 p. S1-S3
3 p.
 artikel
68 Foreword Brummer, Robert-Jan
 2001
 72-73 S1 p. iii-
1 p.
 artikel
69 Foreword Brummer, Robert-Jan
 1999
 72-73 S1 p. iii-
1 p.
 artikel
70 Ghrelin induces expression of the immediateearly genes c-Fos and Egr-1 in the hypothalamic arcuate nucleus: a comparison between fasted and fed rats Hewson, A.K.
 2001
 72-73 S1 p. S160-
1 p.
 artikel
71 Ghrelin, the endogenous ligand to the growth hormone secretagogue receptor — expression in human hypothalamus and pituitary Korbonits, M.
 2001
 72-73 S1 p. S141-
1 p.
 artikel
72 GP1-2: Autocrine human growth hormone suppression of E-CADHERIN via p44/42 MAPK promotes epithelial-tomesenchymal transition (EMT) of colorectal carcinoma cells Wang, J.
 2014
 72-73 S1 p. S25-
1 p.
 artikel
73 GP4-5: Circulating levels of insulin-like growth factor-1(IGF-I)/insulin-like growth factor binding protein-3 (IGFBP-3) in obese patients: the state of type 2 diabetes Kim, M.S.
 2014
 72-73 S1 p. S48-S49
2 p.
 artikel
74 GP2-6: Differential effects of IGFBP-6 on migration of two ovarian cancer cell lines Bach, L.
 2014
 72-73 S1 p. S28-S29
2 p.
 artikel
75 GP3-4: Discordance of post-surgical nadir GH during OGTT and serum IGF-I levels in patients with acromegaly Fukuda, I.
 2014
 72-73 S1 p. S38-
1 p.
 artikel
76 GP4-6: Effects of GH/IGF-I axis on retinal vascular morphology: retinal vascular morphology in Laron syndrome Sekeroglu, H.T.
 2014
 72-73 S1 p. S49-
1 p.
 artikel
77 GP4-2: Effects of heparin administration on the generation of IGFBP-4 fragments during PCI treatment of ST-elevation myocardial infarction patients Hjortebjerg, R.
 2014
 72-73 S1 p. S47-S48
2 p.
 artikel
78 GP4-3: Epigenetic analyses of the insulin-like growth factor binding protein 1 gene in diabetes and diabetic nephropathy Gu, T.
 2014
 72-73 S1 p. S48-
1 p.
 artikel
79 GP3-1: Growth hormone (GH) replacement has a beneficial effect on glycosylated haemoglobin (HbA1c) levels in adult patients with GH deficiency (GHD) enrolled in the NordiNet® International Outcome Study (IOS) Weber, M.M.
 2014
 72-73 S1 p. S37-
1 p.
 artikel
80 GP1-1: Growth hormone targets expression of specific lipolytic genes to promote lipolysis of white adipose tissue Law, Y.Y.
 2014
 72-73 S1 p. S25-
1 p.
 artikel
81 GP2-5: Hyperglycaemia induces chemo-resistance of breast cancer cells via regulating IGFBP-2/oestrogen receptor (ERa) interactions: role of ERa phosphorylation Zeng, L.
 2014
 72-73 S1 p. S28-
1 p.
 artikel
82 GP2-1: IGF-I ameliorates hepatic fibrosis in mouse models of nonalcoholic steatohepatitis and cirrhosis via inhibiting the activity or hepatic stellate cells Nishizawa, H.
 2014
 72-73 S1 p. S27-
1 p.
 artikel
83 GP2-4: Insulin-like growth factor binding protein (IGFBP)-1 and its RGD domain: favorable in vivo actions in glucose regulation Haywood, N.
 2014
 72-73 S1 p. S28-
1 p.
 artikel
84 GP4-1: Loss of PI 3-kinase-binding protein PI3KAP/XB130 suppresses thyroid function and induces enlargement of thyroid glands in mice Yamanaka, D.
 2014
 72-73 S1 p. S29-
1 p.
 artikel
85 GP1-6: Metabolic requirements to sustain NEFA and glucose homeostasis overrides the role of growth hormone in promoting rapid linear growth in hyperphagic MC4RKO mice Tan, H.Y.
 2014
 72-73 S1 p. S37-
1 p.
 artikel
86 GP3-6: Mixed effects PK/PD modelling of NNC0195-0092 - a noncovalent albumin binding growth hormone derivative in the hypophysectomised rat Thygesen, P.
 2014
 72-73 S1 p. S39-
1 p.
 artikel
87 GP1-4: Mortality in patients with non-functioning pituitary adenoma with and without growth hormone replacement therapy. A case-controlled study in more than 400 patients Trimpou, P.
 2014
 72-73 S1 p. S36-
1 p.
 artikel
88 GP1-5: Presurgical somatostatin analogue versus direct surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis, assessing clinical evidence using the GRADE system Nunes, V.S.
 2014
 72-73 S1 p. S36-
1 p.
 artikel
89 GP4-7: ProIGF-II not matureIGF-II promotes estrogen independent breast cancer growth and metastasis in a SCID and Nude mouse model: differential signallng mechanisms thru IGF and Insulin receptors and phosphorylation/activation of estrogen and progesterone receptors Jian, T.
 2014
 72-73 S1 p. S29-S30
2 p.
 artikel
90 GP1-3: Role of growth hormone (GH) signaling pathways in the development of atherosclerosis Ishikawa, M.
 2014
 72-73 S1 p. S26-
1 p.
 artikel
91 GP3-2: Rosiglitazone treatment: acromegaly patients do not differ from normal type 2 diabetics in their IGFBP-1 and Insulin dynamics with euglycemic glucose clamp Tint, M.T.
 2014
 72-73 S1 p. S37-S38
2 p.
 artikel
92 GP4-4: SGA short stature bearing with a novel nonsense mutation (p.W1219X) in the IGF1R gene Fujimoto, M.
 2014
 72-73 S1 p. S48-
1 p.
 artikel
93 GP2-2: The deubiquitinating enzyme, USP9X positively regulates insulin-like growth factor (IGF)-dependent cell growth by inhibition of degradation of IGF-I receptor (IGF-IR) and insulin receptor substrate (IRS)-2 in prostate cancer cells Furuta, H.
 2014
 72-73 S1 p. S27-
1 p.
 artikel
94 GP3-3: The diagnostic accuracy of pegvisomant-primed glucagon stimulation test (PV-GST) compared to insulin tolerance (ITT) and glucagon stimulation (GST) tests in evaluating adult growth hormone (GH) reserve Yuen, K.C.J.
 2014
 72-73 S1 p. S38-
1 p.
 artikel
95 GP2-7: The IGF/IGFR pathway regulates axial patterning during early neural development in mammal Takata, N.
 2014
 72-73 S1 p. S29-
1 p.
 artikel
96 GP2-3: The role of the insulin receptor in breast cancer progression Rostoker, R.
 2014
 72-73 S1 p. S27-S28
2 p.
 artikel
97 GP3-5: Thyroid hormone activation regulates exercise induced growth hormone release Ignacio, D.L.
 2014
 72-73 S1 p. S38-
1 p.
 artikel
98 Growth hormone and ageing van der Lely, A.J.
 1999
 72-73 S1 p. 117-119
3 p.
 artikel
99 Growth hormone and exercise: Physiology, use and abuse Jenkins, Paul J.
 2001
 72-73 S1 p. S71-S77
7 p.
 artikel
100 Growth hormone and insulin-like growth factorI have differential effects on osteoprotegerin and osteoprotegerin ligand gene expression in the human osteoblast cell line MG-63 Kim, B.-J.
 2001
 72-73 S1 p. S158-
1 p.
 artikel
101 Growth hormone conserves nitrogen andaccelerates lipolysis during dietary restriction in obese women Norrelund, H.
 1999
 72-73 S1 p. 151-
1 p.
 artikel
102 Growth hormone deficiency andatherosclerosis — is there a link? McGrath, S.
 1999
 72-73 S1 p. 9-13
5 p.
 artikel
103 Growth hormone deficiency and the risk of cancer Bengtsson, Bengt-Åke
 2000
 72-73 S1 p. S34-
1 p.
 artikel
104 Growth hormone (GH) andatherosclerosis: changes in morphology and function of major arteries during GH treatment Pfeifer, M.
 1999
 72-73 S1 p. 25-30
6 p.
 artikel
105 Growth hormone (GH) replacement therapy: cancer in adults treated with GH Monson, John P.
 2000
 72-73 S1 p. S50-S51
2 p.
 artikel
106 Growth hormone (GH) replacement therapy: cancer in children receiving GH Shalet, Stephen M.
 2000
 72-73 S1 p. S49-
1 p.
 artikel
107 Growth hormone (GH) secretagoguesand neuroendocrine regulation of GH secretion Dickson, S.L.
 1999
 72-73 S1 p. 89-91
3 p.
 artikel
108 Growth hormone (GH) secretion in GH-deficientadults and obese patients: Effect of the administration of acipimox on GH secretion mediated by GH-releasing hormone Cordido, F.
 1999
 72-73 S1 p. 137-
1 p.
 artikel
109 Growth hormone receptorantagonists: Discovery and potential uses Kopchick, John J.
 2001
 72-73 S1 p. S103-S109
7 p.
 artikel
110 Growth hormone receptor associated JAK proteins in the liver: Differences between rats and humans Hellgren, G.
 1999
 72-73 S1 p. 154-
1 p.
 artikel
111 Growth hormone secretagogues:A pill for growth? Clark, R.G.
 1999
 72-73 S1 p. 85-88
4 p.
 artikel
112 Growth hormone secretagogues astherapeutic agents Svensson, J.
 1999
 72-73 S1 p. 107-109
3 p.
 artikel
113 Growth hormone secretion in patients withacromegaly: Effect of acute administration of acipimox Cordido, F.
 1999
 72-73 S1 p. 138-
1 p.
 artikel
114 Growth hormone stimulates expression and DNA-binding activity of CCAAT/enhancer binding protein-α in primary cultures of rat hepatocytes Strand, P.
 1999
 72-73 S1 p. 154-
1 p.
 artikel
115 Growth hormone stimulates synthesis of mannan-binding lectin Hansen, T.K.
 2001
 72-73 S1 p. S131-
1 p.
 artikel
116 Growth hormone therapy with dietary restrictiondecreases insulin resistance by reducing visceral fat and increasing muscle mass in obese patients with type 2 diabetes mellitus Nam, S.Y.
 1999
 72-73 S1 p. 150-
1 p.
 artikel
117 Growth hormone therapy with Genotropin MiniQuick® offers improved convenience Sjöblom, K.
 1999
 72-73 S1 p. 143-
1 p.
 artikel
118 Growth hormone treatment in adults:Is there a true gender difference? Conceição, Flávia Lucia
 2001
 72-73 S1 p. S43-S48
6 p.
 artikel
119 Growth hormone treatment in critical illness — a critical appraisal Isaksson, O.G.P.
 1999
 72-73 S1 p. 83-84
2 p.
 artikel
120 Hard endwpoints for GH replacement therapy: Report from an interactive discussion of bone status and cardiovascular function in GH-deficient adults Jørgensen, J.O.I.
 1998
 72-73 S1 p. 63-67
5 p.
 artikel
121 Height, insulin-like growth factors and cancer risk Gunnell, David
 2000
 72-73 S1 p. S39-S40
2 p.
 artikel
122 High incidence of cardiovascular disease and increased prevalence of cardiovascular risk factors in women with hypopituitarism not receiving growth hormone treatment: Preliminary results Erfurth, E.M.
 1999
 72-73 S1 p. 21-24
4 p.
 artikel
123 Hormone abuse in sport Russell-Jones, D.L.
 1999
 72-73 S1 p. 63-65
3 p.
 artikel
124 Hormone replacement therapy for somatopause: risk–benefit analysis and precedents in the treatment of menopause Lamberts, Stephen W.J.
 2000
 72-73 S1 p. S52-S53
2 p.
 artikel
125 Hospital usage by patients withhypopituitarism Ogunko, A.
 2001
 72-73 S1 p. S132-
1 p.
 artikel
126 Human adipose tissue expresses angiotensinogen and the enzymes required for its conversion to angiotensin II Carlsson, L.
 1999
 72-73 S1 p. 156-
1 p.
 artikel
127 Identification of a peroxisomal targeting signal inthe high-density lipoprotein receptor, scavenger receptor class B type I Johnson, M.S.C.
 1999
 72-73 S1 p. 159-
1 p.
 artikel
128 Impaired tissue perfusion and vascular reactivity in growth hormone-deficient adults is normalized on growth hormone replacement Hána, V.
 2001
 72-73 S1 p. S149-
1 p.
 artikel
129 Impaired vascular reactivity in adults withgrowth hormone deficiency: Evidence of a relationship between endothelial dysfunction and arterial stiffness Smith, J.C.
 2001
 72-73 S1 p. S148-
1 p.
 artikel
130 Increased leptin levels in women withhypopituitarism and childhood-onset growth hormone deficiency Krzyzanowska, B.
 1999
 72-73 S1 p. 152-
1 p.
 artikel
131 Influence of glucocorticoid replacementtherapy on body composition in growth hormone deficient adults: Possible consequences for insulin sensitivity Beentjes, J.A.M.
 1999
 72-73 S1 p. 150-
1 p.
 artikel
132 Influence of hypothyroidism on hypothalamicpituitary growth hormone regulatory systems Miki, N.
 2001
 72-73 S1 p. S133-
1 p.
 artikel
133 Insulin is a more important predictor for leptin than insulin-like growth factor-binding protein 1 and growth hormone Bülow, B.
 2001
 72-73 S1 p. S147-
1 p.
 artikel
134 Insulin-like growth factor 1 and growthhormone-releasing hormone (GHRH) inhibit GHRH receptor gene expression in cultured rat pituitary cells Ono, M.
 2001
 72-73 S1 p. S157-
1 p.
 artikel
135 Insulin-like growth factor-binding proteins and neoplasia: an overview Camacho-Hübner, Cecilia
 2000
 72-73 S1 p. S14-S15
2 p.
 artikel
136 Insulin-like growth factor (IGF-I), IGF-bindingprotein and the acid-labile subunit responses to short-term growth hormone administration in paediatric patients with liver disease Jones, J.S.
 1999
 72-73 S1 p. 162-
1 p.
 artikel
137 Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies Chan, June M.
 2000
 72-73 S1 p. S32-S33
2 p.
 artikel
138 Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses' Health Study Giovannucci, Edward
 2000
 72-73 S1 p. S30-S31
2 p.
 artikel
139 Insulin-like growth factor 1 in a normal adult population, in growth hormone deficiency and in acromegaly: Comparison of an automated system with radioimmunoassay Alexopoulou, O.
 2001
 72-73 S1 p. S140-
1 p.
 artikel
140 Insulin-like growth factor I receptor regulation in prostate carcinoma Roberts Jr, Charles T.
 2000
 72-73 S1 p. S20-S21
2 p.
 artikel
141 Insulin-like growth factor I receptor signalling in prostate cancer cells Baserga, Renato
 2000
 72-73 S1 p. S43-S44
2 p.
 artikel
142 Insulin-like growth factor I stimulate angiogenesis and the production of vascular endothelial growth factor Dunn, Sandra E.
 2000
 72-73 S1 p. S41-S42
2 p.
 artikel
143 Insulin-like growth factor 1 levels within the first year of growth hormone replacement therapy are higher in married men than in single men treated at the same dose Lahner, H.
 2001
 72-73 S1 p. S135-
1 p.
 artikel
144 Insulin-like growth factor physiology and neoplasia Pollak, Michael
 2000
 72-73 S1 p. S6-S7
2 p.
 artikel
145 Insulin-like growth factors and mammographic density Byrne, Celia
 2000
 72-73 S1 p. S24-S25
2 p.
 artikel
146 Insulin-like growth factor signalling pathways in rat hepatic stellate cells: Effects on DNA synthesis and hepatocyte growth factor production Skrtic, S.
 1999
 72-73 S1 p. 155-
1 p.
 artikel
147 Insulin sensitivity and urinary C-peptide excretionin adults with growth hormone (GH) deficiency: Effects of GH replacement therapy Sinay, I.
 1999
 72-73 S1 p. 144-145
2 p.
 artikel
148 Insulin signalling through ultradian oscillations Levy, Jonathan C.
 2001
 72-73 S1 p. S17-S23
7 p.
 artikel
149 In vivo and in vitro expression of somatostatinreceptor subtypes in human pituitary adenomas and correlation to expression of gonadotropin-releasing hormone receptor mRNA Nielsen, S.
 1999
 72-73 S1 p. 158-
1 p.
 artikel
150 Is there a medical need to explore the clinical use of insulin-like growth factor I? Savage, Martin O.
 2001
 72-73 S1 p. S65-S69
5 p.
 artikel
151 Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk Wu, Xifeng
 2000
 72-73 S1 p. S26-S27
2 p.
 artikel
152 Laboratory assessment of GH Strasburger, C.J.
 1998
 72-73 S1 p. 41-46
6 p.
 artikel
153 Leptin and growth hormone during weight loss in severe obesity Cardoso, M.H.
 2001
 72-73 S1 p. S145-
1 p.
 artikel
154 Leptin in adult growth hormone deficiency: Changes with growth hormone replacement are independent of alterations in body fat mass Ahmad, A.M.
 2001
 72-73 S1 p. S143-
1 p.
 artikel
155 Long-term effects of growth hormone (GH) replacement therapy on the body composition of adults with GH deficiency: A 60-month follow-up Troendle, A.
 2001
 72-73 S1 p. S127-
1 p.
 artikel
156 Mechanisms of genomic imprinting Hoffman, Andrew R.
 2000
 72-73 S1 p. S18-S19
2 p.
 artikel
157 Modulation of retinal endothelial cell behaviour by insulin-like growth factor 1 and somatostatin analogues: Implications for diabetic retinopathy Wilson, Sylvia H.
 2001
 72-73 S1 p. S53-S59
7 p.
 artikel
158 Molecular and cell biology ofthe growth hormone-releasing hormone receptor Gaylinn, B.D.
 1999
 72-73 S1 p. 37-44
8 p.
 artikel
159 Monday, 7 November 2016 2016
 72-73 S1 p. S1-S15
15 p.
 artikel
160 Mortality and hypopituitarism Stewart, P.M.
 1999
 72-73 S1 p. 15-19
5 p.
 artikel
161 Mortality, cardiovascular events and risk factors in hypopituitarism Clayton, R.N.
 1998
 72-73 S1 p. 69-76
8 p.
 artikel
162 Neuroendocrinology of the humangrowth hormone-insulin-like growth factor I axis during ageing Arvat, E.
 1999
 72-73 S1 p. 111-115
5 p.
 artikel
163 Neurophysiological regulation andtarget-tissue impact of the pulsatile mode of growth hormone secretion in the human Veldhuis, Johannes D.
 2001
 72-73 S1 p. S25-S37
13 p.
 artikel
164 Nitric oxide and arginine Vallance, P.
 1999
 72-73 S1 p. 31-35
5 p.
 artikel
165 Obesity: A rational target for managing diabetes mellitus Mooradian, Arshag D
 2001
 72-73 S1 p. S79-S83
5 p.
 artikel
166 Observational study in adults with hypopituitarism and untreated growth hormone deficiency: Health and socioeconomic impact Sanmarti, A.
 1999
 72-73 S1 p. 140-
1 p.
 artikel
167 OL Longevity genes: parlor trick or path to drugs that revolutionize medicine Sinclair, D.
 2010
 72-73 S1 p. S1-
1 p.
 artikel
168 OL Posttranscriptional regulation of the insulin and IGF system Gorospe, M.
 2012
 72-73 S1 p. S1-
1 p.
 artikel
169 OL Unravelling the mystery of neuroregulation of growth hormone secretion: the first fifty years Reichlin, S.
 2008
 72-73 S1 p. S1-S2
2 p.
 artikel
170 One-year follow-up of quality of life in adults with untreated growth hormone deficiency Badia, X.
 1999
 72-73 S1 p. 139-
1 p.
 artikel
171 OR3,16 Abnormal MRI in GH-deficient patients: association with clinical presentation, hormonal status and 1st year GH response Deal, C.
 2010
 72-73 S1 p. S8-
1 p.
 artikel
172 OR11,2 A central role of insulin-like growth factor-II in embryonic growth and the development of brain and pancreas in zebrafish Netchine, I.
 2008
 72-73 S1 p. S22-
1 p.
 artikel
173 OR9,3 Acid-labile subunit gene mutations: clinical, biochemical and molecular study in two unrelated families Camacho-Hübner, C.
 2008
 72-73 S1 p. S18-
1 p.
 artikel
174 OR3,17 Acromegaly is associated with enhanced renal and extrarenal epithelial sodium channel (ENaC) activity in humans Kamenicky, P.
 2010
 72-73 S1 p. S9-
1 p.
 artikel
175 OR2,12 Adipokines, and central fat mass have a higher impact on peak GH during the GHRH+arginin test than the insulin tolerance test Klose, M.
 2010
 72-73 S1 p. S6-
1 p.
 artikel
176 OR12,67 Age-dependent control of Akt phosphorylation in muscles from IGFBP-2 transgenic mice as a potential target for the metabolic effects of IGFBP-2 Hoeflich, A.
 2010
 72-73 S1 p. S31-
1 p.
 artikel
177 OR5-3: A GH antagonist fusion with GH binding protein is biologically active, shows delayed clearance and inhibits growth in a rabbit model Wilkinson, I.
 2014
 72-73 S1 p. S14-S15
2 p.
 artikel
178 OR11,4 A monoclonal antibody that targets a novel site on the beta3 subunit of the alphaVbeta3 integrin blocks lesion development in a porcine model of diabetes accelerated atherosclerosis Maile, L.A.
 2008
 72-73 S1 p. S22-
1 p.
 artikel
179 OR5-6: Amplified stem/progenitor cells in a mouse model of prostate tumorigenesis induced by autocrine prolactin Sackmann Sala, L.
 2014
 72-73 S1 p. S15-S16
2 p.
 artikel
180 OR09-4 Analysis of growth hormone, prolactin, and insulin/insulin-like growth factor receptors and ligands in the national cancer institute's 60 cell-line panel covering 9 types of human cancer Gosney, E.S.
 2012
 72-73 S1 p. S24-S25
2 p.
 artikel
181 OR8-4: A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies Sun, J.
 2014
 72-73 S1 p. S22-
1 p.
 artikel
182 OR5,27 A novel approach involving a sensitized chemical mutagenesis screen to identify genes that interact with GH signaling pathway to regulate skeletal phenotype Mohan, S.
 2010
 72-73 S1 p. S12-S13
2 p.
 artikel
183 OR03-2 Anovel GH1 mutation resulting in deletion of amino acids 188–190 is associated with retarded growth Junnila, R.K.
 2012
 72-73 S1 p. S7-
1 p.
 artikel
184 OR2,9 A novel human growth hormone XTEN construct (VRS-317) for once-a-month subcutaneous administration Cleland, J.L.
 2010
 72-73 S1 p. S5-
1 p.
 artikel
185 OR6,3 A novel IGF:IGFBP:vitronectin complex for treatments of wounds Upton, Z.
 2008
 72-73 S1 p. S13-
1 p.
 artikel
186 OR13,73 A novel mechanism to inhibit IGF-I and prevent the development of diabetic retinopathy Maile, L.A.
 2010
 72-73 S1 p. S33-
1 p.
 artikel
187 OR10-4 A novel mutation (p.D1105E) of IGF1R detected in a family of short stature has dominant negative effect to IGF1R, not to IR Kawashima, Y.
 2012
 72-73 S1 p. S27-
1 p.
 artikel
188 OR6,32 A novel role of insulin-like growth factor binding protein (IGFBP)-5 in calcium homeostasis in zebrafish embryos Dai, W.
 2010
 72-73 S1 p. S14-
1 p.
 artikel
189 OR07-5 An overview of the GH-2004 project: Catching the growth hormone cheats Holt, R.I.
 2012
 72-73 S1 p. S19-
1 p.
 artikel
190 OR02-6 AP-1 complex regulates intracellular localization of insulin receptor substrate-1 required for insulin-like growth factor-I-dependent proliferation Yoneyama, Y.
 2012
 72-73 S1 p. S5-S6
2 p.
 artikel
191 OR7-8: A phase II randomised, open-label, parallelgroup study of the safety, tolerability, pharmacokinetics and efficacy of two subcutaneous dosing regimens of ATL1103 in adult patients with acromegaly Trainer, P.J.
 2014
 72-73 S1 p. S21-
1 p.
 artikel
192 OR03-5 A phase 2, multicenter, multiple-dose, open-label, parallel-group, active controlled, safety, tolerability, pharmacokinetic and pharmacodynamic study of ACP-001 in adult patients with Growth Hormone Deficiency (AGHD) Höybye, C.
 2012
 72-73 S1 p. S8-S9
2 p.
 artikel
193 OR7-4: A phase 2, six-month dose-response study to investigate TransCon hGH, a long-acting hGH, in treatment naïve children with idiopathic growth hormone deficiency (IGHD) Chatelain, P.
 2014
 72-73 S1 p. S19-
1 p.
 artikel
194 OR4,24 A phosphoproteomic view of the IGF-II signaling Vallejo, A.F.
 2010
 72-73 S1 p. S11-
1 p.
 artikel
195 OR7-1: A reversible albumin-binding GH derivative possesses a promising once-weekly treatment profile and is well tolerated in adult subjects with growth hormone deficiency Højby Rasmussen, M.
 2014
 72-73 S1 p. S18-
1 p.
 artikel
196 OR05-6 Association of SNP rs11107116 in the vicinity of the suppressor of cytokine signaling 2 (SOCS2) gene with serum IGF-I levels during GH replacement therapy in GHD adults Glad, C.A.M.
 2012
 72-73 S1 p. S14-S15
2 p.
 artikel
197 OR5-5: Autocrine hGH stimulated miRNA 96-182-183 cluster promotes epithelial-mesenchymal transition and invasion in breast cancer Zhang, W.
 2014
 72-73 S1 p. S15-
1 p.
 artikel
198 OR1,1 b cell specific disruption of the growth hormone receptor impair b cell insulin secretion Wu, Y.
 2010
 72-73 S1 p. S2-
1 p.
 artikel
199 OR12,1 Bi-directional resistance pathways relevant to anti-IGF-1R targeted therapy: pathway to clinical development Haluska, P.
 2008
 72-73 S1 p. S23-
1 p.
 artikel
200 OR10-1 Bioactive IGF-I and IGFBP-1 in Danish children and adolescents 3 to 5 years after onset of type 1 diabetes. Effect of residual β-cell function Frystyk, J.
 2012
 72-73 S1 p. S25-S26
2 p.
 artikel
201 OR11-1 Biochemical characterisation of insulin-like growth factor II isoforms associated with tumorigenesis Greenall, S.A.
 2012
 72-73 S1 p. S28-S29
2 p.
 artikel
202 OR14,82 Biochemical markers of bone turnover in tibia fracture patients randomly assigned to growth hormone (GH) or placebo injections. Implications for detection of GH abuse Krusenstjerna-Hafstrøm, T.
 2010
 72-73 S1 p. S36-S37
2 p.
 artikel
203 OR07-6 Biochemical markers of IGF-I misuse: The response of IGF-I and procollagen type III amino-terminal propeptide (P-III-NP) to the administration of recombinant human IGF-I/IGF binding protein-3 in recreational athletes Guha, N.
 2012
 72-73 S1 p. S20-
1 p.
 artikel
204 OR10,3 Bone mineral density in women with Turner syndrome treated with estrogen and growth hormone Abe, K.
 2008
 72-73 S1 p. S20-S21
2 p.
 artikel
205 OR7,3 Bone mineral density is a predictor of adiponectin and visfatin in patients with acromegaly Sucunza, N.
 2008
 72-73 S1 p. S15-
1 p.
 artikel
206 OR9,51 Brown adipose tissue is present in PET negative supraclavicular fat in adult humans Lee, P.
 2010
 72-73 S1 p. S23-S24
2 p.
 artikel
207 OR7,41 Can metabolomics be used to identify new markers of growth hormone deficiency? Hoybye, C.
 2010
 72-73 S1 p. S19-
1 p.
 artikel
208 OR08-4 Cardioprotection by low-dose IGF-1 in myocardial infarct Kelly, G.M.
 2012
 72-73 S1 p. S21-S22
2 p.
 artikel
209 OR05-1 Cardiovascular risk status in childhood cancer survivors with treated vs. untreated growth hormone deficiency Petryk, A.
 2012
 72-73 S1 p. S12-S13
2 p.
 artikel
210 OR1,4 Cause-specific mortality in patients from the KIMS database and associations with IGF-I standard deviation scores (SDS) Wilton, P.
 2008
 72-73 S1 p. S3-
1 p.
 artikel
211 OR6,36 Characterization of a putative ‘BH3-like’ domain establishes IGFBP-3 as a unique intrinsic pathway activator that integrates cell survival and death signals in the mitochondrial regulatory network Paharkova-Vatchkova, V.
 2010
 72-73 S1 p. S16-
1 p.
 artikel
212 OR11,66 Characterization of four human growth hormone mutants found in patients with retarded growth Hennig, M.
 2010
 72-73 S1 p. S30-S31
2 p.
 artikel
213 OR9,1 Chimeric vitronectin: IGF-I proteins enhance cell growth and provide a novel defined culture system for stem cells Van Lonkhuyzen, D.
 2008
 72-73 S1 p. S18-
1 p.
 artikel
214 OR1,5 Chronic growth hormone (GH) excess is associated with increased aldosterone in mice and humans Bidlingmaier, M.
 2008
 72-73 S1 p. S4-
1 p.
 artikel
215 OR07-1 Circulating RNAs as markers of growth hormone doping Kelly, B.N.
 2012
 72-73 S1 p. S18-
1 p.
 artikel
216 OR3,18 Clinical, genetic and molecular characterisation of patients with familial isolated pituitary adenomas (FIPA), especially GH-secreting adenomas Trivellin, G.
 2010
 72-73 S1 p. S9-
1 p.
 artikel
217 OR1-6: Combination medical therapy for acromegaly: the ACROSTUDY experience Strasburger, C.
 2014
 72-73 S1 p. S6-S7
2 p.
 artikel
218 OR7,1 Comparison of the effects of raloxifene and estrogen on growth hormone action in hypopituitary women Birzniece, V.
 2008
 72-73 S1 p. S14-
1 p.
 artikel
219 OR13,78 Compensatory activation of insulin receptor (IR) upon inhibition of insulin-like growth factor-1 receptor (IGF-1R): Rationale for co-targeting IGF-1R and IR in cancer Buck, E.
 2010
 72-73 S1 p. S35-
1 p.
 artikel
220 OR9,50 Components of the IGF system are readily detectable in the interstitial fluid when evacuated by ‘suction blister’ technique Espelund, U.
 2010
 72-73 S1 p. S23-
1 p.
 artikel
221 OR2-6: Cyclic glycine-proline is a regulator that dynamically controls IGF-1 homeostasis through altering IGF-1 binding to IGFBP3 Guan, J.
 2014
 72-73 S1 p. S9-
1 p.
 artikel
222 OR4,1 Defective Smad7 regulation contributes to excess IGFBP-3-dependent collagen I production in intestinal strictures in Crohn's disease Flynn, R.S.
 2008
 72-73 S1 p. S8-
1 p.
 artikel
223 OR5,4 Depot-specific proteomic analysis of adipose tissue from GHR-/- mice Sackmann-Sala, L.
 2008
 72-73 S1 p. S11-
1 p.
 artikel
224 OR6-6: Dermal fibroblast secreted IGF-I protects skin keratinocytes against ultraviolet B radiation induced damage Fernandez, T.L.
 2014
 72-73 S1 p. S17-S18
2 p.
 artikel
225 OR03-1 Development of a platform technology to generate long-acting protein therapeutics Wilkinson, I.R.
 2012
 72-73 S1 p. S6-S7
2 p.
 artikel
226 OR5,5 d3-Growth hormone receptor polymorphism is not linked with modulation of IGF-I response to GH in acromegaly Montefusco, L.
 2008
 72-73 S1 p. S12-
1 p.
 artikel
227 OR08-5 Diacylglycerol kinase ζ, a novel binding partner of insulin receptor substrate, negatively modulated GLUT4 translocation in 3T3-L1 adipocytes Hakuno, F.
 2012
 72-73 S1 p. S22-
1 p.
 artikel
228 OR6-1: Dicarba modification of insulin peptides results in lower mitogenic activity signaled via IGF-1R and IR than insulin Ong, S.C.
 2014
 72-73 S1 p. S16-
1 p.
 artikel
229 OR1,6 Diet induced obesity in growth hormone antagonist mice Yang, T.
 2010
 72-73 S1 p. S4-
1 p.
 artikel
230 OR3,4 Differential dose related GH- and IGF-insensitivity in children with idiopathic short stature and low serum IGF-I: comparison with growth hormone-deficient patients Cohen, P.
 2008
 72-73 S1 p. S7-S8
2 p.
 artikel
231 OR8,48 Differential impacts of IGFBP-3 in epithelial IGF-induced lung cancer development Kim, W.-Y.
 2010
 72-73 S1 p. S21-
1 p.
 artikel
232 OR04-1 Dissection of growth and aging by IGFBP-2 variants: Functional analysis of the Arg-Gly-Asp sequence from IGFBP-2 in transgenic mice Zeissler, A.
 2012
 72-73 S1 p. S9-S10
2 p.
 artikel
233 OR5,30 Distinct epigenetic actions of growth hormone and Stat5b Chia, D.J.
 2010
 72-73 S1 p. S13-S14
2 p.
 artikel
234 OR4,4 D413N mutation of the acid-labile subunit causes defects in secretion and ternary complex formation Baxter, R.C.
 2008
 72-73 S1 p. S9-
1 p.
 artikel
235 OR9,52 Dynamic relationship of IGFBP-1 and insulin during euglycemic glucose clamp in type 2 diabetes restored by rosiglitazone Tint, M.T.
 2010
 72-73 S1 p. S24-
1 p.
 artikel
236 OR6-3: Early postnatal nutritional programming of growth involves GHRH neurons axon growth stimulation by leptin & IGF-I Decourtye, L.
 2014
 72-73 S1 p. S17-
1 p.
 artikel
237 OR01-1 Early postnatal nutrition programs the somatotropic axis through epigenetic mechanism Kappeler, L.
 2012
 72-73 S1 p. S1-S2
2 p.
 artikel
238 OR3,6 Effect of environment on growth: auxological and hormonal parameters in African and normal Italian children Boschetti, M.
 2008
 72-73 S1 p. S8-
1 p.
 artikel
239 OR9,2 Effects of a rowing-step test on saliva IGF-I levels in athletes Antonelli, G.
 2008
 72-73 S1 p. S18-
1 p.
 artikel
240 OR4,22 Effects of IGF-1 receptor heterozygosity on glucose metabolism Garg, N.
 2010
 72-73 S1 p. S10-S11
2 p.
 artikel
241 OR1,4 Effects of low-carbohydrate/high-fat (LCHF) diets on the growth hormone (GH)/insulin like growth factor (IGF) system in rats Stoehr, B.J.M.
 2010
 72-73 S1 p. S3-
1 p.
 artikel
242 OR13,76 Effects of metformin on hyperglycaemia-induced chemoresistance of DU145 and LNCaP prostate cancer cells Biernacka, K.
 2010
 72-73 S1 p. S34-
1 p.
 artikel
243 OR10-2 Effects of raloxifene and estrogen on bioactive IGF-I in healthy and GH-deficient women Birzniece, V.
 2012
 72-73 S1 p. S26-
1 p.
 artikel
244 OR10,4 Effects of two years of growth hormone replacement therapy in adults with GHD in previously treated acromegaly Norrman, L-L.
 2008
 72-73 S1 p. S21-
1 p.
 artikel
245 OR14,79 Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome de Lind van Wijngaarden, R.F.A.
 2010
 72-73 S1 p. S35-
1 p.
 artikel
246 OR04-4 Endogenous insulin-like growth factor binding protein 3 (IGFBP-3) contributes to DNA damage-induced apoptosis in breast cancer cells Marzec, K.A.
 2012
 72-73 S1 p. S10-S11
2 p.
 artikel
247 OR4,23 ER chaperone GRP94 depletion in skeletal muscle reduces muscle and organismal growth through inhibition of IGF-I production Barton, E.
 2010
 72-73 S1 p. S11-
1 p.
 artikel
248 OR7,40 Evaluation of between-methods agreement of extracellular water measurements in adults with growth hormone deficiency (GHD) Barbosa, E.
 2010
 72-73 S1 p. S18-S19
2 p.
 artikel
249 OR2,11 Evidence in support of luminal versus circulating octanoate for ghrelin O-acyl transferase (GOAT)-mediated acylation of ghrelin Thorner, M.O.
 2010
 72-73 S1 p. S6-
1 p.
 artikel
250 OR05-3 Examining the impact of growth hormone on the collagen content of adipose tissue Householder, L.A.
 2012
 72-73 S1 p. S13-S14
2 p.
 artikel
251 OR2-4: Exogenous administration of protease-resistant, non matrixbinding IGFBP-2 inhibits tumour growth in a murine model of breast cancer Soh, C.-L.
 2014
 72-73 S1 p. S8-
1 p.
 artikel
252 OR3,1 Exon 3 deletion polymorphism of the growth hormone receptor (GHR) and GH response: a report of 97 cases (Manchester) and literature meta-analysis Solomon, M.
 2008
 72-73 S1 p. S6-S7
2 p.
 artikel
253 OR12,72 Explore the mechanism of growth hormone signaling with growth hormone receptor monoclonal antibodies Wu, Z.
 2010
 72-73 S1 p. S32-S33
2 p.
 artikel
254 OR1,1 Factors determining inadequate hypoglycaemia during insulin tolerance testing after pituitary surgery Lee, P.
 2008
 72-73 S1 p. S2-
1 p.
 artikel
255 OR8,2 FAS mediates IGF-I-induced mitogenesis of breast cancer cells but not non-malignant breast epithelial cells Jarrett, C.
 2008
 72-73 S1 p. S16-
1 p.
 artikel
256 OR2,5 Fibronectin exposure reduces efficacy of chemotherapeutic agents on DU145 prostate cancer cells: an effect mediated via IGF-I and beta-1 integrin receptors Perks, C.M.
 2008
 72-73 S1 p. S5-
1 p.
 artikel
257 OR02-1 First crystal structure of insulin bound to its primary binding site on the insulin receptor Lawrence, M.
 2012
 72-73 S1 p. S4-
1 p.
 artikel
258 OR03-4 Five months treatment with a long-acting GHRH analog improves cognition in healthy older men and women and in patients with mild cognitive impairment Merriam, G.R.
 2012
 72-73 S1 p. S8-
1 p.
 artikel
259 OR4,20 Free IGF-1 enhances somatic growth and skeletal architecture Courtland, H.-W.
 2010
 72-73 S1 p. S10-
1 p.
 artikel
260 OR2,7 Gender difference in neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators Birzniece, V.
 2010
 72-73 S1 p. S4-
1 p.
 artikel
261 OR11,61 Genetic markers associated with 1 month change in IGF-I and growth at 1 year during GH therapy in children with GH deficiency: The PREDICT study and follow-up highlight genetic contributions to individual response Clayton, P.
 2010
 72-73 S1 p. S28-
1 p.
 artikel
262 OR3-4: GH activated signal transducer and activator of transcription 5 is required for induction of beige fat in inguinal white adipose tissue Nelson, C.N.
 2014
 72-73 S1 p. S10-S11
2 p.
 artikel
263 OR1,3 GH deficiency may impair cognitive and functional recovery after stroke Bondanelli, M.
 2008
 72-73 S1 p. S3-
1 p.
 artikel
264 OR3-2: GH enhances spine density in amygdalar neurons Gisabella, B.
 2014
 72-73 S1 p. S10-
1 p.
 artikel
265 OR5,28 GH-induced activation of JAK/STAT signaling in osteosarcoma cells is inhibited by statins through the induction of SOCS expression Sandoval-Usme, M.C.
 2010
 72-73 S1 p. S13-
1 p.
 artikel
266 OR4,3 Ghrelin reduces hepatic insulin action of IGFBP-1 production Lewitt, M.
 2008
 72-73 S1 p. S9-
1 p.
 artikel
267 OR7,39 GH responsiveness in hypopituitary patients with very severe adult GHD using insulin, arginine or glucagon stimulation tests is associated with IGF-I SDS but not with the stimulated GH peak Feldt-Rasmussen, U.
 2010
 72-73 S1 p. S18-
1 p.
 artikel
268 OR1-1: GH treatment modulates mortality in adult onset GH deficiency and a discordant socio-economic status is apparent Stochholm, K.
 2014
 72-73 S1 p. S5-
1 p.
 artikel
269 OR5,1 Grb10-mediated recruitment of Eps15 to the IGF-IR regulates ligand-dependent receptor internalization and signalling Monami, G.
 2008
 72-73 S1 p. S10-S11
2 p.
 artikel
270 OR12,69 Growth hormone enhances breast cancer chemoresistance by protecting from apoptosis Zatelli, M.C.
 2010
 72-73 S1 p. S31-S32
2 p.
 artikel
271 OR11,64 Growth hormone (GH) induces a dose-dependent, long-term increase in growth in pre-pubertal children with GH deficiency (GHD) without modifying the rate of initiation of puberty Cohen, P.
 2010
 72-73 S1 p. S29-S30
2 p.
 artikel
272 OR05-5 Growth hormone-induced insulin resistance involves reduced pyruvat dehydrogenase activity in skeletal muscle Nellemann, B.
 2012
 72-73 S1 p. S14-
1 p.
 artikel
273 OR4-2: Growth hormone is a more potent growth stimulating hormone than IGF-I: clinical perspective Laron, Z.
 2014
 72-73 S1 p. S12-
1 p.
 artikel
274 OR09-3 Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression Minoia, M.
 2012
 72-73 S1 p. S24-
1 p.
 artikel
275 OR11-2 Growth Hormone regulates the circulating levels of the mitochondria-derived peptide humanin Lee, C.
 2012
 72-73 S1 p. S29-
1 p.
 artikel
276 OR11,63 Growth hormone treatment has a positive effect on spine bone mineral density in young adults with childhood-onset growth hormone deficiency: a meta-analysis Kappelgaard, A.-M.
 2010
 72-73 S1 p. S29-
1 p.
 artikel
277 OR10,55 GSK-3beta regulates insulin-like growth factor receptor tyrosine kinase activity by phosphorylation of S1248 in the C-terminus Kelly, G.M.
 2010
 72-73 S1 p. S25-
1 p.
 artikel
278 OR6,35 Heparin binding properties of the IGF-II/IGFBP-2 complex Lund, J.
 2010
 72-73 S1 p. S15-S16
2 p.
 artikel
279 OR08-3 Hepatic IGF-I production is regulated by Kupffer cells Ishikawa, M.
 2012
 72-73 S1 p. S21-
1 p.
 artikel
280 OR11,5 Hepatic insulin signals are enhanced in rats fed on low-protein diets, a model of IGF resistance Toyoshima, Y.
 2008
 72-73 S1 p. S23-
1 p.
 artikel
281 OR13,2 High dose and not low dose growth hormone treatment reverses type 2 diabetes in mice List, E.
 2008
 72-73 S1 p. S25-
1 p.
 artikel
282 OR9,53 Higher circulating IGF-I bioactivity and total IGF-I with intraperitoneal insulin delivery than with CSII in type 1 diabetes Arnqvist, H.
 2010
 72-73 S1 p. S24-S25
2 p.
 artikel
283 OR6,33 Hyperglycaemia reduces the efficacy of chemotherapeutic agents in DU145 prostate cancer (CaP) cells: Involvement of IGFBP-2 Perks, C.M.
 2010
 72-73 S1 p. S14-S15
2 p.
 artikel
284 OR6,31 Identification and functional characterization of an ancient IGFBP from Amphioxus: Evolution of the IGFBP family Zhou, J.
 2010
 72-73 S1 p. S14-
1 p.
 artikel
285 OR4-5: IGF bioactivity in sera and pleural effusions from patients suspected of lung cancer Espelund, U.
 2014
 72-73 S1 p. S13-
1 p.
 artikel
286 OR9,54 IGFBP-6 and IGF-II: novel mediators of myofibroblast differentiation in Dupuytren's Disease? Raykha, C.
 2010
 72-73 S1 p. S25-
1 p.
 artikel
287 OR11,3 IGFBP-3 as a unique promising therapeutic target for asthma: IGF-independent cross-talk and interference with NF-kB signalling Oh, Y.
 2008
 72-73 S1 p. S22-
1 p.
 artikel
288 OR04-6 IGFBP-3 enhances autophagy to promote breast cancer cell survival during stress Firth, S.M.
 2012
 72-73 S1 p. S11-
1 p.
 artikel
289 OR12,5 IGFBP-5 induces extracellular matrix production via Egr-1 and MAPK-dependent pathways Feghali-Bostwick, C.
 2008
 72-73 S1 p. S24-
1 p.
 artikel
290 OR4,2 IGFBP-1 in women and men during the development of type 2 diabetes Lewitt, M.S.
 2008
 72-73 S1 p. S9-
1 p.
 artikel
291 OR6,34 IGFBP-3 is a metastasis suppression gene for prostate cancer Mehta, H.
 2010
 72-73 S1 p. S15-
1 p.
 artikel
292 OR11-5 IGFBP-2 is a predictor of longitudinal cardiovascular trends in type 2 diabetes Narayanan, R.P.
 2012
 72-73 S1 p. S30-
1 p.
 artikel
293 OR13,5 IGFBP-2 null mice develop obesity and insulin resistance with aging DeMambro, V.E.
 2008
 72-73 S1 p. S26-
1 p.
 artikel
294 OR11-3 IGF-II and neurogenesis: in vitro and in vivo analyses Ziegler, A.N.
 2012
 72-73 S1 p. S29-
1 p.
 artikel
295 OR10-6 IGF-I increases glucose utilization during euglycemic clamps in adolescents with type 1 diabetes mellitus Ekström, K.E.I.
 2012
 72-73 S1 p. S27-S28
2 p.
 artikel
296 OR10,60 IGF-IIR: A novel autocrine loop between IGF-II and hCG Freyre, S.I.
 2010
 72-73 S1 p. S27-
1 p.
 artikel
297 OR13,4 IGF-I is an important niche factor that determines placental mesenchymal stem cell fate via specific cell-signaling mechanisms Iosef, C.
 2008
 72-73 S1 p. S25-S26
2 p.
 artikel
298 OR08-2 IGF-I prevents the development of hepatic fibrosis in nonalcoholic steatohepatitis via regulating oxidative stress and inactivating the hepatic stellate cells Nishizawa, H.
 2012
 72-73 S1 p. S20-S21
2 p.
 artikel
299 OR8,3 IGF-IR and IR quantification and signaling in murine primary mammary epithelial cells Rowzee, A.M.
 2008
 72-73 S1 p. S16-
1 p.
 artikel
300 OR12,4 IGF-IR-dependent activation of Survivin is required in T-antigen-mediated stimulation of proliferation and survival of neural progenitors Gualco, E.
 2008
 72-73 S1 p. S24-
1 p.
 artikel
301 OR4,21 IGF-I receptor blockade ameliorates the smooth muscle hyperplasia and fibrosis of TNBS-induced colitis Flynn, R.S.
 2010
 72-73 S1 p. S10-
1 p.
 artikel
302 OR10,58 IGF-I-responsive ribosomal protein WDR3 integrates 40S ribosome biogenesis with p53-mediated cell cycle regulation O'Connor, R.
 2010
 72-73 S1 p. S26-
1 p.
 artikel
303 OR8,47 IGF-I:Vitronectin interactions modulate breast cancer cell survival, migration and epithelial to mesenchymal transition Upton, Z.
 2010
 72-73 S1 p. S21-
1 p.
 artikel
304 OR12,71 IGF2 promotes murine forebrain neural stem/progenitor cell self-renewal via the insulin receptor Ziegler, A.
 2010
 72-73 S1 p. S32-
1 p.
 artikel
305 OR06-3 IGF regulation of miR-483–3p expression in the developing human placenta Forbes, K.
 2012
 72-73 S1 p. S16-
1 p.
 artikel
306 OR9,4 IGF-1R ubiquitination: from signaling to receptor degradation Girnita, L.
 2008
 72-73 S1 p. S19-
1 p.
 artikel
307 OR04-3 Impact of anti-inflammatory actions of IGFBP-3 in asthma and metabolic syndrome Oh, Y.
 2012
 72-73 S1 p. S10-
1 p.
 artikel
308 OR09-2 Impact of pre-analytical conditions on measured concentrations of compounds of the GH/IGF-system in rats Popp, S.
 2012
 72-73 S1 p. S23-S24
2 p.
 artikel
309 OR2-1: Impaired mTORC1 activity up-regulates IGFBP-1 synthesis during dietary protein restriction Takenaka, A.
 2014
 72-73 S1 p. S7-
1 p.
 artikel
310 OR1-2: Impairment of anaerobic capacity in adults with growth hormone deficiency Chikani, V.
 2014
 72-73 S1 p. S5-
1 p.
 artikel
311 OR01-2 Increased GH signalling independent of IGF-1 is associated with increased bone strength in the SOCS2 knockout mouse Dobie, R.
 2012
 72-73 S1 p. S2-
1 p.
 artikel
312 OR8,44 Increased levels of circulating IGF-I normalizes mammary gland development in mice deficient of local IGF-1 Cannata, D.H.
 2010
 72-73 S1 p. S20-
1 p.
 artikel
313 OR02-5 Insulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of the insulin receptor isoform A Morrione, A.
 2012
 72-73 S1 p. S5-
1 p.
 artikel
314 OR8-7: Insulin like growth factor-II (IGF-II) regulates mitochondrial phenotype, metabolism and DNA content to prevent apoptosis and to increase energy production efficiency promoting a more aggressive and chemoresistant breast cancer disease Radhakrishnan, V.K.
 2014
 72-73 S1 p. S23-
1 p.
 artikel
315 OR12,3 Insulin-like growth factor I protects cells from ER stress-induced apoptosis via enhancement of the adaptive capacity of endoplasmic reticulum Novosyadlyy, R.
 2008
 72-73 S1 p. S24-
1 p.
 artikel
316 OR8-2: Insulin-like growth factor receptor inhibition in mammary epithelium enhances Wnt1- mediated tumors, canonical Wnt signaling and IGF-II/insulin-receptor A expression Wood, T.L.
 2014
 72-73 S1 p. S21-S22
2 p.
 artikel
317 OR13,77 Insulin-like growth factors (IGFs) and IGF binding proteins in PSA-detected prostate cancer: a population-based case control study Rowlands, M.-A.
 2010
 72-73 S1 p. S34-S35
2 p.
 artikel
318 OR10,57 Insulin-like growth factor signaling regulates stem/progenitor cells in the epithelium of virgin mouse mammary glands Lazzarino, D.A.
 2010
 72-73 S1 p. S26-
1 p.
 artikel
319 OR02-2 Insulin receptor (InsR) and insulin-like growth factor-I receptor (IGF-GR) translocate to nucleus and regulate IGF-GR gene expression in breast cancer cells Sarfstein, R.
 2012
 72-73 S1 p. S4-
1 p.
 artikel
320 OR5,2 Insulin receptor substrate (IRS)-1 around endosomes, sorted by adaptor protein (AP)-1, is essential for IGF-I-induced DNA synthesis in L6 myoblasts Matsuo, M.
 2008
 72-73 S1 p. S11-
1 p.
 artikel
321 OR8-1: Insulin receptor substrate (IRS)-1 interacts with protein arginine methyltransferase 5 (PRMT5), emerging as a novel regulator of alternative pre-mRNA splicing Ozoe, A.
 2014
 72-73 S1 p. S21-
1 p.
 artikel
322 OR10,56 Insulin receptor substrate-1 localized around endosomes, sorted by adaptor protein-1 complex, transmits insulin/IGF signals to specific Akt substrates Yoneyama, Y.
 2010
 72-73 S1 p. S26-
1 p.
 artikel
323 OR12,68 Insulin receptor substrates (IRSs) form a complex with RNAs, affecting RNA metabolism and translation Atsufumi, O.
 2010
 72-73 S1 p. S31-
1 p.
 artikel
324 OR9,5 Insulin receptor substrates (IRSs) form a high-molecular-mass complex containing RNAs as well as proteins that function in RNA processing Sone, M.
 2008
 72-73 S1 p. S19-
1 p.
 artikel
325 OR02-3 Insulin receptor substrates (IRSs), interacting with Ras-GAP SH3-domain-binding protein 1 (G3BP1), regulate cap-independent translation of bcl-2 mRNA Ozoe, A.
 2012
 72-73 S1 p. S4-S5
2 p.
 artikel
326 OR7,37 Interaction between testosterone and growth hormone on whole body protein anabolism is mediated through the liver Birzniece, V.
 2010
 72-73 S1 p. S17-
1 p.
 artikel
327 OR2,6 Interrelationship between somatostatin/dopamine pathways and growth factors in non-small lung cancer cells Arvigo, M.
 2008
 72-73 S1 p. S5-S6
2 p.
 artikel
328 OR6,5 Intramyocellular lipids during exercise: comparison of growth hormone deficient patients and endurance trained athletes Egger, A.
 2008
 72-73 S1 p. S13-
1 p.
 artikel
329 OR03-6 Intranasal administration of Human Growth Hormone (CP024) and induction of IGF-1 in healthy volunteers Jordan, F.
 2012
 72-73 S1 p. S9-
1 p.
 artikel
330 OR06-6 IRS2-deficient mice show sensorineural hearing loss that is delayed by concomitant PTP1B loss of function Varela-Nieto, I.
 2012
 72-73 S1 p. S17-
1 p.
 artikel
331 OR6-2: IRS-1 promotes embryonic growth of zebrafish through IGF-IR signal-dependent and -independent mechanisms in response to developmental stages and environmental oxygen availability Kamei, H.
 2014
 72-73 S1 p. S16-
1 p.
 artikel
332 OR2-5: Linkage of reproductive development, fat metabolism and lifespan by the RGD-motif of IGFBP-2 in female transgenic mice Hoeflich, A.
 2014
 72-73 S1 p. S9-
1 p.
 artikel
333 OR11,1 Liver-derived circulating IGF-I is sufficient to restore linear growth in an IGF-I null mouse Wu, Y.
 2008
 72-73 S1 p. S21-
1 p.
 artikel
334 OR11,6 Liver-derived IGF-I regulates life span in mice Svensson, J.
 2008
 72-73 S1 p. S23-
1 p.
 artikel
335 OR3-3: Liver-specific (LiGHRKO) and fat-specific (FaGHRKO) growth hormone receptor gene disrupted mice demonstrate paradoxical longevity and provide evidence for GH stimulated liver/adipose tissue-crosstalk List, E.O.
 2014
 72-73 S1 p. S10-
1 p.
 artikel
336 OR13,74 Longevity and age-related pathology of mice deficient in pregnancy-associated plasma protein-A Conover, C.A.
 2010
 72-73 S1 p. S33-
1 p.
 artikel
337 OR11-6 Long-term mortality in patients with isolated GHD, ISS, and SGA treated with recombinant GH during childhood in Sweden: Application of a mortality model developed from the general population Wikland, K. Albertsson
 2012
 72-73 S1 p. S30-S31
2 p.
 artikel
338 OR08-6 Long-term treatment with TNF-α represses GKAP42 binding to IRS-1 causing impairment of insulin signaling through IRS-1 and insulin-dependent glucose uptake in 3T3-L1 adipocytes Ando, Y.
 2012
 72-73 S1 p. S22-
1 p.
 artikel
339 OR3-6: Loss of acyl-ghrelin signalling in male ghrelin-O-acyltransferase knock-out mice results in reduced pulsatile growth hormone secretion and a derangement of GH pulse pattern Xie, T.Y.
 2014
 72-73 S1 p. S11-
1 p.
 artikel
340 OR4,19 Loss of neuronal IGF receptors increases somatotropic hormone signaling and accelerates aging in mice Xu, J.
 2010
 72-73 S1 p. S9-S10
2 p.
 artikel
341 OR10-3 Low circulating levels of Insulin-Like Growth factor-I (IGF-I) are associated with a reduced beta-cell function and disposition index in healthy adult males Thankamony, A.
 2012
 72-73 S1 p. S26-
1 p.
 artikel
342 OR6,4 Marked reductions in bioactive IGF-I during hemodialysis Ivarsen, P.
 2008
 72-73 S1 p. S13-
1 p.
 artikel
343 OR7,38 Measurement of free GH and bioactive IGF-I in non-diabetic hemodialysis patients treated with rh-GH for 7 days Frystyk, J.
 2010
 72-73 S1 p. S17-S18
2 p.
 artikel
344 OR07-3 Measurement of serum IGF-1 by LC-MS-MS: A multi-site validation study for anti-doping testing Bowers, L.D.
 2012
 72-73 S1 p. S18-S19
2 p.
 artikel
345 OR5-1: Mechanism of activation of JAK2 by growth hormone Waters, M.J.
 2014
 72-73 S1 p. S14-
1 p.
 artikel
346 OR10,59 Mechanism of regulation of placental mesenchymal stem cell (PMSC) fate by insulin-like growth factors (IGFs) under low oxygen tension Youssef, A.
 2010
 72-73 S1 p. S26-S27
2 p.
 artikel
347 OR2,10 Metabolic effects of tesamorelin, a growth hormone-releasing hormone analogue, in HIV-infected patients with excess abdominal fat: a pooled analysis of 2 multicenter, randomized, placebo-controlled phase 3 trials Falutz, J.
 2010
 72-73 S1 p. S5-S6
2 p.
 artikel
348 OR5,3 Nedd4 interacts with insulin receptor substrate (IRS)-1 and IRS-2 leading to enhancement of IGF signals through the PI 3-kinase pathway in a different manner Fukushima, T.
 2008
 72-73 S1 p. S11-
1 p.
 artikel
349 OR4,6 New insights into metabolism from IGFBP-3 knockout mice Yamada, P.M.
 2008
 72-73 S1 p. S10-
1 p.
 artikel
350 OR8-5: Novel mechanisms by which Nedd4-IRS-2 complexes enhance IGF-I signals, and their roles in IGF-I action in prostate cancer cell proliferation Fukushima, T.
 2014
 72-73 S1 p. S22-S23
2 p.
 artikel
351 OR3-5: NPY neurons as a critical hypothalamic node for the control of GH release relative to food intake Huang, L.
 2014
 72-73 S1 p. S11-
1 p.
 artikel
352 OR14,80 Octreolin™, a safe oral alternative for parenteral octreotide treatment Tuvia, S.
 2010
 72-73 S1 p. S35-S36
2 p.
 artikel
353 OR3,2 Optimization of first year height velocity in short children born SGA by individual GH dose adjustment Land, C.
 2008
 72-73 S1 p. S7-
1 p.
 artikel
354 OR10,5 Outcome of quality of life and body composition after discontinuation of growth hormone in adult hypopituitary patients — a randomised placebo-controlled trial Filipsson, H.
 2008
 72-73 S1 p. S21-
1 p.
 artikel
355 OR8,4 Overexpression of IRS-1 suppresses initiation of myogenesis through exclusion of Foxo1 from the nucleus in the PI 3-kinase-dependent mechanism Yamauchi, Y.
 2008
 72-73 S1 p. S16-S17
2 p.
 artikel
356 OR06-2 Overexpression of microRNA 145 reveals a role for maternal IGF1R in mediating embryo-epithelial juxtacrine communication at implantation Kang, Y.-J.
 2012
 72-73 S1 p. S15-S16
2 p.
 artikel
357 OR12,2 p125, a novel PI 3-kinase-associated protein (PITKAP) plays an essential role in cAMP-dependent potentiation of IGF bioactivities in a thyroid cell line Yamanaka, D.
 2008
 72-73 S1 p. S23-S24
2 p.
 artikel
358 OR7-7: Pasireotide LAR provides superior efficacy over octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: a phase III, multicenter, randomized study (PAOLA) Fleseriu, M.
 2014
 72-73 S1 p. S20-S21
2 p.
 artikel
359 OR01-3 Pathophysiology of renal calcium handling in acromegaly: What lies behind hypercalciuria? Kamenicky, P.
 2012
 72-73 S1 p. S2-
1 p.
 artikel
360 OR3,15 Pegvisomant added to somatostatin analogue treatment increases intrahepatic but decreases intramuscular lipid content in acromegalic patients Madsen, M.
 2010
 72-73 S1 p. S8-
1 p.
 artikel
361 OR7,2 Pharmacokinetic and pharmacodynamic characterisation of NNC 126-0083, a long-acting growth hormone derivative Thygesen, P.
 2008
 72-73 S1 p. S14-S15
2 p.
 artikel
362 OR2,8 Phase I PK&PD profile of long acting bio-better CTP modified hGH (MOD-4023) in healthy volunteers Havron, A.
 2010
 72-73 S1 p. S4-S5
2 p.
 artikel
363 OR10-5 Phase I study of figitumumab and pegvisomant in patients with advanced solid tumors Haluska, P.
 2012
 72-73 S1 p. S27-
1 p.
 artikel
364 OR02-4 Phosphatidylinositol 3-kinase-binding protein, PI3KAP/XB130 crosslinks actin filaments and regulates cell migration Yamanaka, D.
 2012
 72-73 S1 p. S5-
1 p.
 artikel
365 OR06-1 Physiological low-oxygen tension mediates the Insulin-Like Growth Factor (IGFs) induced signal transduction in Placental Mesenchymal Stem Cell (PMSC) towards enhanced multipotency via polycomb group proteins Youssef, A.
 2012
 72-73 S1 p. S15-
1 p.
 artikel
366 OR09-6 Placental growth hormone (GHV) is the predominant growth hormone transcript in MCF7 breast cancer cells Herpy, J.
 2012
 72-73 S1 p. S25-
1 p.
 artikel
367 OR3,3 Polymorphisms associated with changes in serum IGF-I after GH therapy in children with GHD or Turner syndrome Clayton, P.
 2008
 72-73 S1 p. S7-
1 p.
 artikel
368 OR2,2 Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis Koyama, S.
 2008
 72-73 S1 p. S4-
1 p.
 artikel
369 OR05-4 Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality: Results from a 10-year follow-up of the Study of Health Pomerania (SHIP) Haring, R.
 2012
 72-73 S1 p. S14-
1 p.
 artikel
370 OR5,26 Post-receptor changes in GH signaling pathway of the epiphyseal growth plate in a rat model of chronic kidney disease related growth retardation Wiezel, D.
 2010
 72-73 S1 p. S12-
1 p.
 artikel
371 OR05-2 Pregnancies and live births in a large cohort of patients on growth hormone replacement therapy Vila, G.
 2012
 72-73 S1 p. S13-
1 p.
 artikel
372 OR01-5 Prevalence of AIP gene mutations in young patients with acromegaly Schöfl, C.
 2012
 72-73 S1 p. S3-
1 p.
 artikel
373 OR11-4 Prevalence of posttraumatic growth hormone deficiency is highly dependent on the diagnostic set-up – results from The Danish National study on posttraumatic hypopituitarism Klose, M.
 2012
 72-73 S1 p. S29-S30
2 p.
 artikel
374 OR04-5 Prohibitin-2 is a binding protein for IGFBP-6 on rhabdomyosarcoma cell membranes and modulates IGFBP-6-dependent migration Bach, L.
 2012
 72-73 S1 p. S11-
1 p.
 artikel
375 OR2,3 Pro-survival growth hormone signaling is activated in response to IGF knockdown in prostate cancer Cobb, L.
 2008
 72-73 S1 p. S4-S5
2 p.
 artikel
376 OR4,5 Proteolysis of IGFBP-5 in pregnancy Firth, S.M.
 2008
 72-73 S1 p. S9-S10
2 p.
 artikel
377 OR5-2: Rabbits are a suitable animal model for the pre-clinical development of growth hormone agonists and antagonists Bielohuby, M.
 2014
 72-73 S1 p. S14-
1 p.
 artikel
378 OR4-1: Randomised controlled clinical trial contrasting current GH doses with dose based on IGF-I titration in children born small for gestational age (NESGAS) Jensen, R.B.
 2014
 72-73 S1 p. S12-
1 p.
 artikel
379 OR11,65 Randomized controlled trial on the effects of growth hormone therapy and nutritional supplementation in boys with constitutional growth delay Han, J.C.
 2010
 72-73 S1 p. S30-
1 p.
 artikel
380 OR07-4 Regulation of fuel metabolism during acute exercise in hypopituitarism with growth hormone-deficiency (GHD) Christ, E.
 2012
 72-73 S1 p. S19-
1 p.
 artikel
381 OR13,6 Regulation of IGF-I receptor signaling and the CUL7 ubiquitin ligase by the Parkinson's Disease protein GIGYF2 Tsiaras, W.G.
 2008
 72-73 S1 p. S26-
1 p.
 artikel
382 OR01-6 Regulation of pituitary growth hormone synthesis by sirtuin 1 Theodoropoulou, M.
 2012
 72-73 S1 p. S3-
1 p.
 artikel
383 OR06-5 Rescue of the age-dependent decline in cerebral glucose uptake by PEGylated IGF-I treatment in a non-human primate Metzger, F.
 2012
 72-73 S1 p. S16-
1 p.
 artikel
384 OR14,83 rhGH/rhIGF-1 co-administration versus rhGH alone in short, prepubertal children with low IGF-1 and normal stimulated GH levels: first-year results from a Phase II, randomized, open-label, active-treatment controlled trial Midyett, L.K.
 2010
 72-73 S1 p. S37-
1 p.
 artikel
385 OR1,2 Risk factors for pituitary dysfunction following moderate or severe traumatic brain injury (TBI) Prodam, F.
 2008
 72-73 S1 p. S3-
1 p.
 artikel
386 OR8-3: Role of deubiquitinase USP7 in signalling through IGF-1R Worrall, C.
 2014
 72-73 S1 p. S22-
1 p.
 artikel
387 OR12,70 Role of GH-IGF-I excess on periodontal tissues Bondanelli, M.
 2010
 72-73 S1 p. S32-
1 p.
 artikel
388 OR1,5 Role of growth hormone signaling pathways in liver regeneration Ishikawa, M.
 2010
 72-73 S1 p. S3-S4
2 p.
 artikel
389 OR13,75 Role of IGF-I and IGFBPs in the fasting-induced protection of mice versus malignant cells against chemotherapy Lee, C.
 2010
 72-73 S1 p. S33-S34
2 p.
 artikel
390 OR8,1 Role of PTEN in IGF-I signalling on astrocytes Fernández, S.
 2008
 72-73 S1 p. S16-
1 p.
 artikel
391 OR8,46 ROS Accumulation and IGF-IR inhibition contribute to fenofibrate/PPARa-mediated inhibition of glioma cell motility in vitro Reiss, K.
 2010
 72-73 S1 p. S20-S21
2 p.
 artikel
392 OR4-3: Safety and effectiveness of Increlex® therapy in children enrolled in the Increlex Growth Forum Database (IGFD) in Europe: 4-year interim results Bang, P.
 2014
 72-73 S1 p. S12-S13
2 p.
 artikel
393 OR7-6: Safety and efficacy of ARX201: six month dose-ranging study of a novel long-acting pegylated growth hormone in young adults with growth hormone deficiency Racz, K.
 2014
 72-73 S1 p. S20-
1 p.
 artikel
394 OR7-3: Safety and efficacy results of a 6 month, randomized, multicenter trial of a novel long-acting rhGH (VRS-317) in naïve to treatment, pre-pubertal children with GH deficiency Bright, G.M.
 2014
 72-73 S1 p. S18-S19
2 p.
 artikel
395 OR7-5: Safety, tolerability, pharmacokinetics and pharmacodynamics of TV-1106, a new long-acting treatment for growth hormone deficiency CohenBarack, O.
 2014
 72-73 S1 p. S19-
1 p.
 artikel
396 OR8-8: Serum IGF-I measured longitudinally during pre-school years - relation to gender, body size, and nutrition such as essential fatty acids and vitamin D Dahlgren, J.
 2014
 72-73 S1 p. S23-S24
2 p.
 artikel
397 OR06-4 Serum insulin-like growth factor (IGF)-1 is insufficient to restore body size in the absence of growth hormone receptor Wu, Y.
 2012
 72-73 S1 p. S16-
1 p.
 artikel
398 OR7,42 Serum proteomic profiles in GH-deficient patients before and after GH substitution Cruz-Topete, D.
 2010
 72-73 S1 p. S19-
1 p.
 artikel
399 OR6-5: Sexual dimorphism of insulin like growth factor I in exercise Munive Herrera, V.A.
 2014
 72-73 S1 p. S17-
1 p.
 artikel
400 OR6,2 Short stature caused by a novel heterozygous mutation in the IGF-I gene van Duyvenvoorde, H.A.
 2008
 72-73 S1 p. S12-
1 p.
 artikel
401 OR1-5: Short-term low dose GH therapy improves insulin sensitivity but does not affect cortisol metabolism and ectopic fat accumulation in GH deficient adults Yuen, K.C.J.
 2014
 72-73 S1 p. S6-
1 p.
 artikel
402 OR08-1 Short-term treatment of old-aged recipient rats with recombinant human growth hormone (rhGH) improves liver repopulation by transplanted hepatocytes Stock, P.
 2012
 72-73 S1 p. S20-
1 p.
 artikel
403 OR09-5 Signal tranducer and activator of transcription 5 mediates the anti-obesity actions of growth hormone Nelson, C.N.
 2012
 72-73 S1 p. S25-
1 p.
 artikel
404 OR07-2 Simultaneous stimulation of human 20 kDa growth hormone and 22 kDa growth hormone secretion by ghrelin Tong, J.
 2012
 72-73 S1 p. S18-
1 p.
 artikel
405 OR5,25 Sirt1 negatively regulates IGF-I production by growth hormone in hepatocytes Yamamoto, M.
 2010
 72-73 S1 p. S12-
1 p.
 artikel
406 OR04-2 Site directed mutagenesis of specific phosphorylation sites in human IGFBP-1 markedly decreases binding affinity for IGF-I and increases IGF-I function Gupta, M.
 2012
 72-73 S1 p. S10-
1 p.
 artikel
407 OR3-1: Spatial learning, memory and signaling cross-talk: genomic and behavioral analysis in wild type versus GH modified (bGH & GHA) mice Basu, A.
 2014
 72-73 S1 p. S9-S10
2 p.
 artikel
408 OR2,1 Starvation-dependent differential stress resistance protects normal but not cancer cells against high dose chemotherapy Longo, V.
 2008
 72-73 S1 p. S4-
1 p.
 artikel
409 OR1,3 Stimulation of growth by a constitutively activated GHR and study of GHR signaling in early development of zebrafish Sun, Y.-H.
 2010
 72-73 S1 p. S3-
1 p.
 artikel
410 OR5,29 Structural and functional role of the C-terminal disulfide bridge of human growth hormone Junnila, R.K.
 2010
 72-73 S1 p. S13-
1 p.
 artikel
411 OR8,43 Structural insights into the binding of peptide agonists and antagonists to the Type 1 insulin-like growth factor receptor ectodomain – mimicking growth factor or mimicking the receptor? Lawrence, M.C.
 2010
 72-73 S1 p. S19-S20
2 p.
 artikel
412 OR1-4: Successful GH treatment for severe growth failure in pediatric patients with anorexia nervosa Fjellestad-Paulsen, A.
 2014
 72-73 S1 p. S6-
1 p.
 artikel
413 OR14,81 SUN11031 (synthetic human Ghrelin) improves lean body mass and function in advanced COPD cachexia in a placebo controlled trial Gertner, J.
 2010
 72-73 S1 p. S36-
1 p.
 artikel
414 OR9,49 Suppression of insulin signaling in white adipose tissues contributes to preferential lipid accumulation in rat liver under protein malnutrition Toyoshima, Y.
 2010
 72-73 S1 p. S22-S23
2 p.
 artikel
415 OR6-4: Sustained IGF-II production is necessary for adult neurogenesis Ziegler, A.N.
 2014
 72-73 S1 p. S17-
1 p.
 artikel
416 OR1,2 Targeted ablation of growth hormone receptors in the skeletal muscle improves metabolism and protects against diet-induced obesity in mice Vijayakumar, A.
 2010
 72-73 S1 p. S2-
1 p.
 artikel
417 OR6,1 Telomere length is associated with exceptional longevity and is modulated by the IGF system Atzmon, G.
 2008
 72-73 S1 p. S12-
1 p.
 artikel
418 OR10,1 Ten-year GH replacement in elderly GH deficient adults increases bone mineral density Svensson, J.
 2008
 72-73 S1 p. S20-
1 p.
 artikel
419 OR8-6: The anti-IGF signaling agents increase the efficacy of Trabectedin in Ewing sarcoma Garofalo, C.
 2014
 72-73 S1 p. S23-
1 p.
 artikel
420 OR2-3: The Cardin-Weintraub Motif present in IGFBP-2 is required for growth and function of the mouse brain Schindler, N.
 2014
 72-73 S1 p. S8-
1 p.
 artikel
421 OR4-4: The causal role of IGFs and IGFBPs in prostate cancer: a Mendelian randomization study Bonilla, C.
 2014
 72-73 S1 p. S13-
1 p.
 artikel
422 OR5-4: The choice of growth hormone receptor signalling pathway determines longevity Chhabra, Y.
 2014
 72-73 S1 p. S15-
1 p.
 artikel
423 OR2,4 The development of multi-dimensional models of serum IGF-I, -II, IGFBP-2 and -3 using artificial neural networks as “composite biomarkers” to predict colorectal cancer Renehan, A.
 2008
 72-73 S1 p. S5-
1 p.
 artikel
424 OR7,5 The diagnosis of growth hormone deficiency after adult height achievement Secco, A.
 2008
 72-73 S1 p. S15-S16
2 p.
 artikel
425 OR11,62 The effect of genotype on molecular mechanisms leading to the 3-M primordial growth disorder Coulson, T.
 2010
 72-73 S1 p. S28-S29
2 p.
 artikel
426 OR4-6: The expression of insulin-like growth factor type 1 receptor (IGF1R) is increased in obese children Ricco, R.C.
 2014
 72-73 S1 p. S13-S14
2 p.
 artikel
427 OR8,45 The IGF-I inducible pyrimidine nucleotide carrier (PNC1) regulates mitochondrial biogenesis and the invasive phenotype of cancer cells Favre, C.
 2010
 72-73 S1 p. S20-
1 p.
 artikel
428 OR13,1 The impact of fasting on growth hormone signaling and action in muscle and fat tissue in human subjects Moller, L.
 2008
 72-73 S1 p. S25-
1 p.
 artikel
429 OR3,14 The influence of IGF-I normalization on cardiovascular risk in patients with uncontrolled and long-term acromegaly in comparison to matched data from the general population Berg, C.
 2010
 72-73 S1 p. S7-S8
2 p.
 artikel
430 OR2-2: The mitochondrial peptide humanin has fasting mimetic activity leading to suppression of circulating IGF-I and increases in IGFBP-1 levels Xiao, J.
 2014
 72-73 S1 p. S7-S8
2 p.
 artikel
431 OR7-2: The MOD-4023 story; a long acting GH from proof of concepts in animal models to growth hormone deficient populations clinical studies (adults and pediatric ) Hart, G.
 2014
 72-73 S1 p. S18-
1 p.
 artikel
432 OR1-3: The molecular mechanism of dominantly inherited short stature caused by GH polymers Wu, Z.
 2014
 72-73 S1 p. S5-S6
2 p.
 artikel
433 OR8,5 The molecular mechanism underlying enhanced breast cell migration stimulated by IGF-I:IGFBP-5:VN complexes Hollier, B.
 2008
 72-73 S1 p. S17-
1 p.
 artikel
434 OR13,3 The role of autocrine human growth hormone in radioresistance of mammary carcinoma cells Bougen, N.
 2008
 72-73 S1 p. S25-
1 p.
 artikel
435 OR3,5 The role of IGF1 system in mediating estrogen effects on growth and epiphyseal proliferation in males: insight from peripubertal aromatase deficiency model Werther, G.
 2008
 72-73 S1 p. S8-
1 p.
 artikel
436 OR09-1 The role of zinc binding and the cellular zinc content in regulated growth hormone secretion Petkovic, V.
 2012
 72-73 S1 p. S23-
1 p.
 artikel
437 OR7,4 The somatotroph response to acylated ghrelin is refractory to the negative GH auto-feedback, but is sensitive to negative IGF-I feedback in man Riganti, F.
 2008
 72-73 S1 p. S15-
1 p.
 artikel
438 OR10,2 Three years safety and efficacy of a novel once-a-week sustained release rhGH (LB03002) in treatment-naive prepubertal children with GHD* Peter, F.
 2008
 72-73 S1 p. S20-
1 p.
 artikel
439 OR3,13 Tumor recurrence and enlargement during more than 10 years growth hormone replacement therapy in patients with craniopharyngioma Olsson, D.S.
 2010
 72-73 S1 p. S7-
1 p.
 artikel
440 OR14,84 Twelve months safety and efficacy of LB03002, a new prolonged release formulation of rhGH, as compared to daily rhGH therapy in treatment-naïve children with growth failure due to insufficient secretion of endogenous growth hormone (GHD) Saenger, P.H.
 2010
 72-73 S1 p. S37-S38
2 p.
 artikel
441 OR03-3 Use of an orally active ghrelin mimetic, macimorelin (AEZS-130), as a safe, simple test for adult GH deficiency: Effect of BMI on optimal cutoff Merriam, G.R.
 2012
 72-73 S1 p. S7-S8
2 p.
 artikel
442 OR01-4 Validation of a novel approach for the detection of acromegaly with automatic face classification using photographs from the internet Schneider, H.J.
 2012
 72-73 S1 p. S2-S3
2 p.
 artikel
443 Overview of breast cancer population studies Hankinson, Susan E.
 2000
 72-73 S1 p. S22-S23
2 p.
 artikel
444 Overview of insulin-like growth factor physiology Holly, Jeff M.P.
 2000
 72-73 S1 p. S8-S9
2 p.
 artikel
445 Overview of pulse actions in the human Albers, Norbert
 2001
 72-73 S1 p. S39-S42
4 p.
 artikel
446 P-33 ACTH releasing activity of GH releasing peptide-2 in patients with hypothalamo-pituitary diseases Yamakado, Y.
 2008
 72-73 S1 p. S37-
1 p.
 artikel
447 P-11 Activation of cAMP responsive element binding protein 1 (CREB1) by stimulation of the Src/ERK pathway is a common mechanism underlying IGF-I receptor upregulation by androgens and estrogens in prostate cancer cells Genua, M.
 2008
 72-73 S1 p. S30-
1 p.
 artikel
448 P03-5 Activity of a pancreatic β-cell-specific two-chain product of the IGF-II gene: Vesiculin Lee, K.L.
 2012
 72-73 S1 p. S72-S73
2 p.
 artikel
449 P29 Acyl-ghrelin secretion declines over a 37.5-h fast in healthy young men Nass, R.
 2010
 72-73 S1 p. S50-
1 p.
 artikel
450 P-27 Adapting and validating Eastern European language versions of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) McKenna, S.
 2008
 72-73 S1 p. S35-
1 p.
 artikel
451 P01-31 A deubiquitinating enzyme, USP7, is associated with insulin receptor substrate (IRS)-2 forming a negative feedback loop in insulin/IGF signaling Yoshihara, H.
 2012
 72-73 S1 p. S43-
1 p.
 artikel
452 P02-25 Adipokine levels in mice with altered Growth Hormone (GH) action over lifespan: Identifying the links between adiposity, insulin sensitivity and longevity Lubbers, E.R.
 2012
 72-73 S1 p. S62-
1 p.
 artikel
453 P03-33 Adult mortality and morbidity in childhood-onset growth hormone deficient patients who received pediatric GH treatment – analysis of the Hypopituitary Control and Complications Study (HypoCCS) Mo, D.
 2012
 72-73 S1 p. S83-
1 p.
 artikel
454 P03-42 Altered social outcomes in patients growing up with a hypothalamic pituitary condition: Data fromthe KIMS database Gleeson, H.
 2012
 72-73 S1 p. S86-S87
2 p.
 artikel
455 P16 Amino-terminal propeptide of C-type natriuretic peptide (NTproCNP): reference range and levels in children with idiopathic short stature treated with growth hormone Olney, R.C.
 2010
 72-73 S1 p. S45-
1 p.
 artikel
456 P-80 Analysis of cellular effects of epigenetic mutations at the IGF2/H19 locus in Silver–Russell syndrome Kannenberg, K.
 2008
 72-73 S1 p. S50-
1 p.
 artikel
457 P48 Analysis of novel mTOR targets during oligodendrocyte differentiation Cifelli, S.E.
 2010
 72-73 S1 p. S56-S57
2 p.
 artikel
458 P01-21 Analysis of the effects of insulin analogues on proliferation and differentiation in skin keratinocytes Solomon, R.
 2012
 72-73 S1 p. S39-
1 p.
 artikel
459 P64 Analysis of the interplay between the insulin receptor and IGF-I receptor signaling pathways in prostate cancer Weinstein, D.
 2010
 72-73 S1 p. S62-
1 p.
 artikel
460 P02-26 A network analysis of gene expression through childhood highlights changes related to both age and growth Stevens, A.
 2012
 72-73 S1 p. S62-S63
2 p.
 artikel
461 P02-50 A new cause of GH deficiency: Mutation in the nuclear encoded mitochondrial isoleucyl tRNA-synthetase (IARS2) in 3 patients with severe short stature, cataracts and peripheral neuropathy Deal, C.
 2012
 72-73 S1 p. S68-
1 p.
 artikel
462 P03-19 Animal model based on IGF-I: Differences in hepatic gene expression of insulin like growth factor binding proteins and liver deiodinase 1 in late pregnant dairy cows with different total IGF-I plasma concentrations Piechotta, M.
 2012
 72-73 S1 p. S78-
1 p.
 artikel
463 P26 An individualized, target-driven treatment regimen for children with idiopathic short stature (ISS) Wajnrajch, M.P.
 2010
 72-73 S1 p. S49-
1 p.
 artikel
464 P-66 An observational, controlled study to compare the prevalence and severity of cardiovascular disease in childhood onset vs. adulthood onset growth hormone deficiency Colao, A.
 2008
 72-73 S1 p. S46-
1 p.
 artikel
465 P02-48 A novel long acting human growth hormone (VRS-317): sustained and dose dependent biological activity in growth hormone deficient adults Bright, G.M.
 2012
 72-73 S1 p. S67-
1 p.
 artikel
466 P63 A novel role of the insulin-like growth factor-II receptor (IGF-IIR) in the regulation of the biological effects of IGFs in a trophoblast cell line Vallejo, A.
 2010
 72-73 S1 p. S61-
1 p.
 artikel
467 P02-40 Anti-IGF1 receptor immunoliposomes: A single formulation combining two anticancer treatments with enhanced therapeutic efficiency Hantel, C.
 2012
 72-73 S1 p. S57-
1 p.
 artikel
468 P103 Anti-Müllerian Hormone (AMH) in short girls born Small for Gestational Age (SGA) and the effect of growth hormone (GH) treatment Lem, A.
 2010
 72-73 S1 p. S78-
1 p.
 artikel
469 P02-38 Antitumor activity of Pasireotide (SOM230) alone and in combination with Everolimus (RAD001) in DU-145 human prostate cancer model Schmid, H.A.
 2012
 72-73 S1 p. S56-S57
2 p.
 artikel
470 P01-4 Antitumor effect of ridaforolimus (MK-8669) in combination with dalotuzumab (MK-0646) and aromatase inhibitor letrozole in a postmenopausal breast cancer model Hou, X.
 2012
 72-73 S1 p. S34-
1 p.
 artikel
471 P59 Antitumor response of preclinical tumor models to IGF-IR targeted therapy is not dependent on PTEN or PIK3CA mutational status Deevi, D.S.
 2010
 72-73 S1 p. S60-
1 p.
 artikel
472 P56 A nuclear complex of Rictor and IRS2 is associated with albuminuria in diabetic mice Mascarenhas, D.
 2010
 72-73 S1 p. S59-
1 p.
 artikel
473 P-48 A PK/PD model for characterisation of NNC 126-0083, a long-acting growth hormone derivative with respect to efficacy, time of duration and dose selection Thygesen, P.
 2008
 72-73 S1 p. S41-
1 p.
 artikel
474 P-81 A possible role of IGF system in the abnormal bone formation in achondroplastic subjects Palermo, C.
 2008
 72-73 S1 p. S50-S51
2 p.
 artikel
475 P-45 A potential role for growth hormone in injury-induced neurogenesis in the immature rat brain Christophidis, L.
 2008
 72-73 S1 p. S40-
1 p.
 artikel
476 P03-20 A proteomics approach to characterising insulin receptor phosphorylation In response to metabolic and mitogenic ligands McCarthy, P.
 2012
 72-73 S1 p. S78-
1 p.
 artikel
477 P72 Are IGFBP-1 and leptin predictor of diabetes in children and adults with low birth weight? Kistner, A.
 2010
 72-73 S1 p. S64-
1 p.
 artikel
478 P02-32 Ascites from women with ovarian carcinoma contains an elevated in vitro IGF-bioactivity as compared with serum Thomsen, J.
 2012
 72-73 S1 p. S54-
1 p.
 artikel
479 P03-29 Association of change in insulin-like growth factor (IGF)-I and IGF-binding protein 3 after 1 month of growth hormone (GH) therapy with genetic markers and long-term growth on GH in children with GH deficiency or Turner's syndrome Clayton, P.
 2012
 72-73 S1 p. S81-
1 p.
 artikel
480 P02-7 Associations of the DHEAs and IGF with cognitive and mental health parameters in the KORA age population: An epidemiologic perspective on neuroendocrine mechanisms Emeny, R.T.
 2012
 72-73 S1 p. S51-
1 p.
 artikel
481 P45 Autocrine role of the IGF-II/IGF-IIR system in trophoblastic cell differentiation Alarcón, J.C.
 2010
 72-73 S1 p. S55-S56
2 p.
 artikel
482 P02-19 Auxology, GH-IGF-I status and response to rhGH in 3-M syndrome Hanson, D.
 2012
 72-73 S1 p. S60-
1 p.
 artikel
483 P22 Baseline characteristics and effects of ten years of growth hormone (GH) replacement therapy in adults previously treated with pituitary irradiation therapy Elbornsson, M.
 2010
 72-73 S1 p. S47-S48
2 p.
 artikel
484 P18 Baseline characteristics and quality of life in patients with childhood-onset growth hormone deficiency due to Cushing's disease and non-functioning pituitary adenoma Ragnarsson, O.
 2010
 72-73 S1 p. S46-
1 p.
 artikel
485 P02-9 Better first year HbA1c in type 1 diabetes mellitus adolescents on long acting insulin analogs vs. NPH insulin is not associated with reversal of their IGF-I deficiency Salemyr, J.
 2012
 72-73 S1 p. S51-S52
2 p.
 artikel
486 P02-42 Bioavailability of Pegvisomant 30mg/mL formulation compared to 15mg/mL Formulation: Pharmacokinetics, safety, and tolerability in healthy subjects Jen, J.
 2012
 72-73 S1 p. S65-
1 p.
 artikel
487 P90 Biomarkers of growth hormone doping in healthy human subjects Ding, J.
 2010
 72-73 S1 p. S72-
1 p.
 artikel
488 P71 Biomarkers of inflammation and nutrition in female Olympic athletes Hagmar, M.
 2010
 72-73 S1 p. S64-
1 p.
 artikel
489 P01-40 BMI and sex have major impact on GH peak levels during the GHRH-Arginine test – establishment of normative data applying a newly developed immunoassay Petersenn, S.
 2012
 72-73 S1 p. S46-
1 p.
 artikel
490 P01-9 BMS-754807 and metformin synergistically inhibit breast and ovarian cancer cell proliferation Becker, M.A.
 2012
 72-73 S1 p. S35-S36
2 p.
 artikel
491 P-26 Body mass index (BMI) and waist circumference in growth hormone (GH)-untreated adult-onset hypopituitarism in relation to age-dependent general population normative data Koltowska-Haggstrom, M.
 2008
 72-73 S1 p. S34-S35
2 p.
 artikel
492 P-23 Bone mineral density and alkaline phosphatase in growth hormone-treated GH-deficient young adults Conway, G.S.
 2008
 72-73 S1 p. S33-S34
2 p.
 artikel
493 P39 Both the insulin receptor isoform a and the IGF-I receptor mediate the effects of IGF-II in human thyroid stem cells Malaguarnera, R.
 2010
 72-73 S1 p. S53-S54
2 p.
 artikel
494 P106 Can IGFBP-1 level predict hepatic steatosis? Gupta, R.
 2010
 72-73 S1 p. S79-
1 p.
 artikel
495 P-95 Carnosine up-regulates liver IGF-I and decreases tissue cholesterol Santos, E.
 2008
 72-73 S1 p. S55-
1 p.
 artikel
496 P02-27 Challenges encountered in the development of an in vivo mouse model system for testing growth hormone antagonist molecules Bielohuby, M.
 2012
 72-73 S1 p. S63-
1 p.
 artikel
497 P30 Characterization of growth hormone disulfide-linked molecular isoforms during post-exercise release vs. nocturnal pulsatile release reveals similar milieu composition Nind, B.C.
 2010
 72-73 S1 p. S50-
1 p.
 artikel
498 P02-36 Circulating levels of IGF-binding proteins in GH transgenic and GH receptor -/- mice Funk, K.R.
 2012
 72-73 S1 p. S56-
1 p.
 artikel
499 P01-41 Clinical features of Hypophysitis Muraoka, T.
 2012
 72-73 S1 p. S46-S47
2 p.
 artikel
500 P37 Comparative study of the IGF system biological effects in HPV positive and negative cervical cancer cell lines Garay-Baquero, D.
 2010
 72-73 S1 p. S53-
1 p.
 artikel
501 P-41 Comparison of growth promoting effect of rhGH and rh IGF-I in patients with isolated GHD type IA Horikawa, R.
 2008
 72-73 S1 p. S39-
1 p.
 artikel
502 P03-40 Comparison of intuitiveness, ease of use and preference in five growth hormone injection devices Kappelgaard, A.-M.
 2012
 72-73 S1 p. S86-
1 p.
 artikel
503 P11 Comparison of intuitiveness, ease of use and preference in three growth hormone injection devices Kappelgaard, A.-M.
 2010
 72-73 S1 p. S42-S43
2 p.
 artikel
504 P83 Comparison of the serum levels of insulin-like growth factor 1, IGF binding protein 1 with their mRNA levels expressed in human carotid plaques Wang, J.
 2010
 72-73 S1 p. S69-
1 p.
 artikel
505 P-74 Congenital IGF-I deficiency effects on dental morphology and histology in patients with Laron syndrome Wright, T.
 2008
 72-73 S1 p. S49-
1 p.
 artikel
506 P53 Continuous activation of IGF signaling inhibits myogenic differentiation of L6 myoblasts Hakuno, F.
 2010
 72-73 S1 p. S58-
1 p.
 artikel
507 P-49 Control of IGF-1 and headache during medical treatment in acromegaly Sanno, N.
 2008
 72-73 S1 p. S41-
1 p.
 artikel
508 P-76 Correlation between N-terminal pro-B-type natiuretic peptide and left ventricular mass in acromegaly Romanello, G.
 2008
 72-73 S1 p. S49-
1 p.
 artikel
509 P03-16 Correlations of adiponectin with IGFBP-1 in Swedish men with and without type 2 diabetes Gu, H.F.
 2012
 72-73 S1 p. S77-
1 p.
 artikel
510 P49 Cortical bone accrual in the adult mouse is unaffected by reductions in serum IGF-1 after peak bone acquisition Courtland, H.-W.
 2010
 72-73 S1 p. S57-
1 p.
 artikel
511 P03-39 Cross-sectional studies are prone to selection bias; example from the Danish national study on posttraumatic hypopituitarism Klose, M.
 2012
 72-73 S1 p. S85-
1 p.
 artikel
512 P-105 CXCR4 expression in lymphocytes of IGF-I deficient mice infected with an intracellular pathogen Cuervo-Escobar, S.
 2008
 72-73 S1 p. S58-
1 p.
 artikel
513 P-64 Decreased p44/42 MAPK phosphorylation in gender- or hormone-related but not during age-related adrenal gland growth in mice Bielohuby, M.
 2008
 72-73 S1 p. S46-
1 p.
 artikel
514 P51 Defective chemotaxis of lymphoid cells to L. monocytogenes infection in serum IGF-I restricted mice Cuervo-Escobar, S.
 2010
 72-73 S1 p. S57-S58
2 p.
 artikel
515 P61 Deficiency of insulin-like growth factor 1 receptor confers resistance to oxidative stress in C2C12 myoblasts Thakur, S.
 2010
 72-73 S1 p. S61-
1 p.
 artikel
516 P92 Determining reliable threshold limits for the GH-2000 detection methodology using 496 samples collected from elite athletes and current IGF-I & P-III-P assay methodologies Erotokritou-Mulligan, I.
 2010
 72-73 S1 p. S73-
1 p.
 artikel
517 P02-21 Development of a new growth hormone receptor antagonist Götsch, F.
 2012
 72-73 S1 p. S61-
1 p.
 artikel
518 P02-56 Development of methods for the sensitive measurement of pulsatile growth hormone in mice Le Tissier, P.
 2012
 72-73 S1 p. S70-S71
2 p.
 artikel
519 P02-23 Differential effects of GH versus IGF-1 during obesity List, E.O.
 2012
 72-73 S1 p. S61-
1 p.
 artikel
520 P91 Differential effects of growth hormone and insulin-like growth factor-1 on the mouse plasma proteome Ding, J.
 2010
 72-73 S1 p. S72-S73
2 p.
 artikel
521 P47 Differential effects of IGF-I, IGF-II and insulin in human preadipocytes and adipocytes – role of insulin and IGF-I receptors Bäck, K.
 2010
 72-73 S1 p. S56-
1 p.
 artikel
522 P-61 Differential signaling by insulin and insulin-like growth factors upon binding to insulin receptor isoform A Sacco, A.
 2008
 72-73 S1 p. S45-
1 p.
 artikel
523 P01-3 Discoidin domain receptor 1 is a new mediator of insulin receptor in breast cancer cells Morcavallo, A.
 2012
 72-73 S1 p. S33-S34
2 p.
 artikel
524 P02-46 Diurnal variation in the pharmacokinetics of growth hormone administered as a continuous subcutaneous infusion in GH-deficient subjects Janukonyte, J.
 2012
 72-73 S1 p. S66-
1 p.
 artikel
525 P03-34 Dose-dependent response of Δ insulin-like growth factor I and Δ height to long-term growth hormone therapy in short Japanese children born small for gestational age Horikawa, R.
 2012
 72-73 S1 p. S83-S84
2 p.
 artikel
526 P01-37 Dose sparing effect of an IGF-I-based dosing regimen in short children treated with Growth Hormone in a 2-Year randomized controlled trial: Therapeutic and pharmacoeconomic considerations Cohen, P.
 2012
 72-73 S1 p. S45-
1 p.
 artikel
527 P31 Earlier start of puberty in GH treated children born SGA than in GH treated for GHD. Data from the NordiNet® IOS Rakov, V.
 2010
 72-73 S1 p. S51-
1 p.
 artikel
528 P-40 Economic evaluation of somatropin (Norditropin®) for the treatment of short children born SGA in Sweden Twena, N.
 2008
 72-73 S1 p. S39-
1 p.
 artikel
529 P02-31 Effect of different treatments on production of recombinant human growth hormone in CHO cells Zarkesh-Esfahani, S.H.
 2012
 72-73 S1 p. S64-
1 p.
 artikel
530 P87 Effect of exenatide, sitagliptin and vildagliptin on IGF-I in diabetic patients Gatto, F.
 2010
 72-73 S1 p. S71-
1 p.
 artikel
531 P50 Effect of GH/IGF-1 supplementation in ALS-deficient mice Courtland, H.-W.
 2010
 72-73 S1 p. S57-
1 p.
 artikel
532 P-37 Effect of GH therapy on coronary flow reserve, diastolic filling and cardiovascular risk factors in adult GHD Boschetti, M.
 2008
 72-73 S1 p. S38-
1 p.
 artikel
533 P108 Effect of intensive insulin therapy on the somatotropic axis in critically ill children Gielen, M.
 2010
 72-73 S1 p. S80-
1 p.
 artikel
534 P01-46 Effect of short term Growth Hormone (GH) replacement on whole body bone mineral measures of children with Growth Hormone Deficiency (GHD) Khadgawat, R.
 2012
 72-73 S1 p. S48-
1 p.
 artikel
535 P01-15 Effect of short-term treatment with insulin on decreased IGF-I expression and increased liver triglycerides during protein deprivation Ozaki, Y.
 2012
 72-73 S1 p. S37-
1 p.
 artikel
536 P95 Effects of GH and IGF-1 treatments on body composition, glucose metabolism and hepatic gene expression in obese/diabetic mice with nonalcoholic fatty liver disease List, E.O.
 2010
 72-73 S1 p. S74-S75
2 p.
 artikel
537 P-07 Effects of GHR stimulation and blockade on growth of prostate cancer cell lines Strawbridge, R.J.
 2008
 72-73 S1 p. S28-S29
2 p.
 artikel
538 P01-23 Effects of IGFBP-1 and IGFBP-2 fragments on migration and IGF-induced proliferation of human dermal fibroblasts Brandt, K.
 2012
 72-73 S1 p. S39-S40
2 p.
 artikel
539 P03-23 Effects of targeting p53/Mdm2/IGF-1R axis on skin melanoma migration, invasion and metastasis Worrall, C.
 2012
 72-73 S1 p. S79-
1 p.
 artikel
540 P23 Effects of 3-year growth hormone (GH) replacement therapy on bone mineral density in younger and elderly adults with adult onset GH deficiency Elbornsson, M.
 2010
 72-73 S1 p. S48-
1 p.
 artikel
541 P01-47 Effects of 10 years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset Svensson, J.
 2012
 72-73 S1 p. S48-S49
2 p.
 artikel
542 P01-17 Elevated serum IGF-I concentrations and accelerated aging in long-term growth selected mouse lines Langhammer, M.
 2012
 72-73 S1 p. S37-S38
2 p.
 artikel
543 P78 Elimination of acute drug side effects without loss of efficacy by site-specific PEGylation of insulin-like growth factor I Metzger, F.
 2010
 72-73 S1 p. S67-
1 p.
 artikel
544 P03-35 Elucidation of mechanism underlying growth retardation caused by human growth hormone mutant E74K Kircheva, Z.I.
 2012
 72-73 S1 p. S84-
1 p.
 artikel
545 P03-10 Epigenetic reprogramming of IGFBP-2 in prostate cancer mediates hyperglycaemia-induced chemoresistance and the effect of metformin Biernacka, K.
 2012
 72-73 S1 p. S74-
1 p.
 artikel
546 Perturbations of the hypothalamic-pituitary-adrenalaxis and the metabolic syndrome in ageing Björntorp, P.
 1999
 72-73 S1 p. 121-123
3 p.
 artikel
547 P-78 Estimates of the bioactivity of IGF-II in serum from healthy subjects, obese subjects and obese type 2 diabetic patients Frystyk, J.
 2008
 72-73 S1 p. S50-
1 p.
 artikel
548 P02-30 Estrogen regulates exercise-induced pituitary type 1 deiodinase increase and growth hormone secretion Ignacio, D.L.
 2012
 72-73 S1 p. S64-
1 p.
 artikel
549 P01-7 Evaluation of the biological actions of insulin analogues in endometrial cancer cell lines Aizen, D. Balas
 2012
 72-73 S1 p. S35-
1 p.
 artikel
550 P03-43 Evolving growth hormone deficiency in patients previously thought to have idiopathic short stature Regelmann, M.O.
 2012
 72-73 S1 p. S87-
1 p.
 artikel
551 P01-27 Expression of IGF2 and IGF1R in pediatric adrenocortical tumors (ACT): Overexpression of IGF1R is associated with unfavorable event and metastasis in adrenocortical carcinomas Lira, R.C.P.
 2012
 72-73 S1 p. S41-
1 p.
 artikel
552 P57 Expression of myosin heavy chain isoforms is mediated by IGF-IEa and IGF-IEb Matheny, W.
 2010
 72-73 S1 p. S59-S60
2 p.
 artikel
553 P98 Extreme body growth and protein accretion under normal serum IGF-I concentrations in male but not in female mice – new models and new challenges for the somatomedin hypothesis Sawitzky, M.
 2010
 72-73 S1 p. S75-S76
2 p.
 artikel
554 P03-31 Factors affecting IGF-I response to Growth Hormone (GH) replacement therapy during transition in patients with childhood-onset GH deficiency Thankamony, A.
 2012
 72-73 S1 p. S82-
1 p.
 artikel
555 P01-49 Familial acromegaly and familial prolactinoma cases in Hungary Déenes, J.
 2012
 72-73 S1 p. S49-
1 p.
 artikel
556 P01-6 Fenofibrate-mediated inhibition of IGF-I receptor signaling responses and its contribution to anticancer treatment Reiss, K.
 2012
 72-73 S1 p. S34-S35
2 p.
 artikel
557 P24 Fifteen-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency Elbornsson, M.
 2010
 72-73 S1 p. S48-
1 p.
 artikel
558 P02-47 First interim results from an international phase IV study in short children born small for gestational age (SGA) treated with Omnitrope® (rhGH) Schwarz, H.-P.
 2012
 72-73 S1 p. S67-
1 p.
 artikel
559 P03-12 Functional dysregulation of immune responses in a Balb/c model deficient in circulating IGF-I due to protein malnutrition and infected with Leishmania (Leishmania) infantum Cuervo-Escobar, S.
 2012
 72-73 S1 p. S75-
1 p.
 artikel
560 P44 Functional study on beta-arrestins involvement in Ras induced transformation of mammalian cells Zheng, H.
 2010
 72-73 S1 p. S55-
1 p.
 artikel
561 P-89 Function and regulation of insulin-like growth factor binding protein-2 and -3 in ovarian cancer cell models Schuett, B.S.
 2008
 72-73 S1 p. S53-
1 p.
 artikel
562 P-44 Gender related IGF-I changes after two years of growth hormone (GH) treatment in GH deficient (GHD) children and adults. Data from the NordiNet® International Outcome Study (IOS) Sävendahl, L.
 2008
 72-73 S1 p. S40-
1 p.
 artikel
563 P01-22 Genome-wide analysis of cancer protection pathways in Laron Syndrome patients Lapkina, L.
 2012
 72-73 S1 p. S39-
1 p.
 artikel
564 P-73 GF-I treatment of patients with Laron syndrome suppresses thrombopoietin levels but does not affect erythropoietin Shevah, O.
 2008
 72-73 S1 p. S48-
1 p.
 artikel
565 P02-24 GH deficiency does not account for metabolic changes in adult patients with craniopharyngioma Roemmler, J.
 2012
 72-73 S1 p. S62-
1 p.
 artikel
566 P-39 GH Deficiency following traumatic brain injury (TBI) as a cause of female infertility Giampietro, A.
 2008
 72-73 S1 p. S38-
1 p.
 artikel
567 P-59 GH fragment measurements: a new laboratory tool for GH state investigation in humans De Palo, E.F.
 2008
 72-73 S1 p. S44-
1 p.
 artikel
568 P02-45 Ghrelin and growth hormone levels are decreased in Saudi autistic children Al-Zaid, F.
 2012
 72-73 S1 p. S66-
1 p.
 artikel
569 P9 Ghrelin test: a new tool for the diagnosis of GH deficiency in adults Gasco, V.
 2010
 72-73 S1 p. S42-
1 p.
 artikel
570 P03-45 GH retesting and lipid profile in childhood-onset GHD when reaching final adult height Wacharasindhu, S.
 2012
 72-73 S1 p. S88-
1 p.
 artikel
571 P02-28 Growth hormone analogues with protracted effect through pegylation or non-covalent albumin binding Thygesen, P.
 2012
 72-73 S1 p. S63-
1 p.
 artikel
572 P02-53 Growth Hormone: a potential biomarker for disease progression in Amyotrophic Lateral Sclerosis (ALS) Ngo, S.T.
 2012
 72-73 S1 p. S69-S70
2 p.
 artikel
573 P-30 Growth hormone deficiency and acromegaly have comparable effects on bone mass and osteoporotic fracture risk in adult women Mazziotti, G.
 2008
 72-73 S1 p. S36-
1 p.
 artikel
574 P-31 Growth hormone does not affect cardiac function in men with the metabolic syndrome and obstructive sleep apnea Franco, C.
 2008
 72-73 S1 p. S36-
1 p.
 artikel
575 P102 Growth hormone-induced oscillations in cytosolic free Ca2+ in single rat hepatocytes, modulation by different agonists Marrero, I.
 2010
 72-73 S1 p. S77-S78
2 p.
 artikel
576 P-02 Growth hormone induces chemoresistance in breast cancer cells Zatelli, M.C.
 2008
 72-73 S1 p. S27-
1 p.
 artikel
577 P5 Growth hormone treatment for iatrogenic Cushing's syndrome Choi, Y.-J.
 2010
 72-73 S1 p. S41-
1 p.
 artikel
578 P03-30 Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome Höybye, C.
 2012
 72-73 S1 p. S82-
1 p.
 artikel
579 P-19 Growth hormone treatment increases obstructive sleep apnea index and neck soft tissue mass in abdominally obese men Koranyi, J.
 2008
 72-73 S1 p. S32-
1 p.
 artikel
580 P-20 Growth hormone treatment in patients on hemodialysis is associated with an increase in serum mannose-binding lectin levels Hansen, T.K.
 2008
 72-73 S1 p. S33-
1 p.
 artikel
581 P-46 Growth hormone treatment in postmenopausal women, effects on aerobic working capacity and the heart Berggren, A.
 2008
 72-73 S1 p. S40-S41
2 p.
 artikel
582 P-94 Growth hormone treatment prevents loss of lean mass after bariatric surgery in morbidly obese patients. Results of a pilot, open, prospective, randomized, controlled study Savastano, S.
 2008
 72-73 S1 p. S54-
1 p.
 artikel
583 Pharmacological testing for thediagnosis of growth hormone deficiency Carel, J.-C.
 1998
 72-73 S1 p. 1-8
8 p.
 artikel
584 P-55 Hearing loss in patients with Laron syndrome (primary growth hormone insensitivity) is reversed by early IGF-I replacement therapy Attias, J.
 2008
 72-73 S1 p. S43-
1 p.
 artikel
585 P03-32 Height outcome in late diagnosed growth hormone (GH) deficiency type II with GH-1 gene mutation (GH-R178H) affecting secretion and action: Use of higher than standard dose GH and pubertal suppression to optimise final height Buchanan, C.R.
 2012
 72-73 S1 p. S82-S83
2 p.
 artikel
586 P-01 HER receptor signaling confers resistance to the insulin-like growth factor 1 receptor inhibitor, BMS-536924 Haluska, P.
 2008
 72-73 S1 p. S27-
1 p.
 artikel
587 P-17 Heterogeneous clinical presentation in patients with yet-unreported type 1 IGF receptor molecular defects Azzi, S.
 2008
 72-73 S1 p. S32-
1 p.
 artikel
588 P-65 High fat/low carbohydrate diets: effects on serum IGF-I and bone growth in rats Bielohuby, M.
 2008
 72-73 S1 p. S46-
1 p.
 artikel
589 P03-22 High glucose enhanced the inhibitory effect of mast cell chymase on the IGF-I-stimulated proliferation of rat aortic smooth muscle cells Wang, J.
 2012
 72-73 S1 p. S79-
1 p.
 artikel
590 P-86 High molecular mass forms of IGFBP-1 associated with placental cell membranes Masnikosa, R.
 2008
 72-73 S1 p. S52-
1 p.
 artikel
591 P-52 High risk of hypopituitarism in patients who recovered from hemorrhagic fever with renal syndrome Stojanovic, M.
 2008
 72-73 S1 p. S42-
1 p.
 artikel
592 P-51 24-h mean acyl-ghrelin levels are decreased in older adults Nass, R.
 2008
 72-73 S1 p. S42-
1 p.
 artikel
593 P-84 Human microvascular endothelial cells are sensitive to IGF-I but insensitive to insulin Johansson, G.S.
 2008
 72-73 S1 p. S51-
1 p.
 artikel
594 P03-7 Hyperglycaemia, IGFs and insulin affect alternative splicing of the insulin receptor in DU145 prostate cancer cells Wang, J.
 2012
 72-73 S1 p. S73-
1 p.
 artikel
595 P03-15 Hyperglycemia confers resistance to antibodies targeting growth factor receptors on breast cancer cells Zeng, L.
 2012
 72-73 S1 p. S76-
1 p.
 artikel
596 P10 Hypopituitarism following traumatic brain injury and subarachnoid hemorrhage: a prospective study Jonasdottir, A.D.
 2010
 72-73 S1 p. S42-
1 p.
 artikel
597 P104 Identification of a novel cell death receptor (IGFBP-3R) mediating IGFBP-3-induced antitumor effects in human cancer Oh, Y.
 2010
 72-73 S1 p. S78-S79
2 p.
 artikel
598 P01-35 Identification of BRCA1 as a biomarker for IGF-GR targeted therapy in breast cancer Cohen-Sinai, T.
 2012
 72-73 S1 p. S44-
1 p.
 artikel
599 P01-20 Identification of microRNAs involved in regulating IGF signalling in the first trimester placenta Farrokhnia, F.
 2012
 72-73 S1 p. S38-S39
2 p.
 artikel
600 P55 Identification of the IAP binding site for SHPS-1 and its role in the regulation of IGF-I signaling Maile, L.A.
 2010
 72-73 S1 p. S59-
1 p.
 artikel
601 P01-18 IGFBP-2 acts as a survival factor for breast cancer cells: Role of ER-α Zeng, L.
 2012
 72-73 S1 p. S38-
1 p.
 artikel
602 P70 IGFBP-2 acts as a survival factor in breast cancer cells Foulstone, E.
 2010
 72-73 S1 p. S63-S64
2 p.
 artikel
603 P73 IGFBP-2 enhances VEGF gene promoter activity and angiogenic activities in neuroblastoma cells Azar, W.J.
 2010
 72-73 S1 p. S65-
1 p.
 artikel
604 P-91 IGFBP-3 in cellular senescence; molecular and clinical implications Garza, A.E.
 2008
 72-73 S1 p. S53-S54
2 p.
 artikel
605 P03-24 IGFBP-2 is a novel regulator of the estrogen receptor in breast epithelial cells Zeng, L.
 2012
 72-73 S1 p. S80-
1 p.
 artikel
606 P01-28 IGF-1-cGP axis and its role in maintaining homeostasis IGF-1 bioactivity Guan, J.
 2012
 72-73 S1 p. S41-S42
2 p.
 artikel
607 P01-11 IGF-I acts as a potent chemotactic factor for spleen lymphocytes Escobar, S.A. Cuervo
 2012
 72-73 S1 p. S36-
1 p.
 artikel
608 P-43 IGF-I and hemoglobin during GH treatment in children born SGA Rapaport, R.
 2008
 72-73 S1 p. S39-S40
2 p.
 artikel
609 P03-21 IGF-I and the resumption of ovarian activity in cows Obese, F.Y.
 2012
 72-73 S1 p. S78-S79
2 p.
 artikel
610 P02-14 IGF-I as a diagnostic tool in feline medicine: Evaluation of an ELISA Strage, E.
 2012
 72-73 S1 p. S53-S54
2 p.
 artikel
611 P01-30 IGF-I deficiency predisposes to presbycusis and noise-induced hearing loss in a mice model Murillo-Cuesta, S.
 2012
 72-73 S1 p. S42-
1 p.
 artikel
612 P01-29 IGF-I-dependent intestinal fibrosis in Crohn's1 disease and TNBS-induced colitis is regulated by αVβ3 integrin Kuemmerle, J.F.
 2012
 72-73 S1 p. S42-
1 p.
 artikel
613 P65 IGF-I-FOXO3a counteracts high glucose/TNFa-mediated neuronal damage in vitro: associations with HIV dementia Wilk, A.
 2010
 72-73 S1 p. S62-
1 p.
 artikel
614 P02-39 IGF-II analogue improves placental efficiency, modifies placental growth and reduces fetal weight distribution in normal mice Charnock, J.C.
 2012
 72-73 S1 p. S57-
1 p.
 artikel
615 P-08 IGF-I, IGFBP-3 and cancer risk: poor performance on discrimination analysis as an explanation of inconsistencies between risk-association studies Renehan, A.G.
 2008
 72-73 S1 p. S29-
1 p.
 artikel
616 P-87 IGF-I:IGFBP-3 molar ratio and disease risk: statistical considerations and level of agreement with free IGF-I Renehan, A.G.
 2008
 72-73 S1 p. S52-
1 p.
 artikel
617 P86 IGF-I/IGFBP-1 system in young subjects newly diagnosed with type 1 Diabetes Mellitus Forsberg, E.
 2010
 72-73 S1 p. S70-
1 p.
 artikel
618 P-98 IGF II immunohistochemistry in breast cancer (BC). Relationship with several predictive parameters in breast malignancy Giustarini, E.
 2008
 72-73 S1 p. S56-
1 p.
 artikel
619 P03-17 IGF-I on the dark side: Negative consequences of IGF-I on mitochondrial homeostasis Sell, C.
 2012
 72-73 S1 p. S77-
1 p.
 artikel
620 P-71 IGF-I recovers mitochondrial function in critically ill patients Horikawa, R.
 2008
 72-73 S1 p. S48-
1 p.
 artikel
621 P-106 IGF-I regulates protein oxidation by modulating proteasome activity Torres, C.
 2008
 72-73 S1 p. S58-
1 p.
 artikel
622 P01-2 IGF-I treatment unveils cell-context dependent regulation of frataxin Franco, C.
 2012
 72-73 S1 p. S33-
1 p.
 artikel
623 P01-14 IGF-I: Vitronectin interactions modulate changes in expression of genes which induce breast cancer cell survival and migration Kashyap, A.S.
 2012
 72-73 S1 p. S36-S37
2 p.
 artikel
624 P01-32 IGF-1 mediates embryo-epithelial juxtacrine communication at implantation through the osteopontin-integrin αvβ3 system Kang, Y.-J.
 2012
 72-73 S1 p. S43-
1 p.
 artikel
625 P-15 IGF pathway in neuroendocrine cancer: expression and prognostic role Cascella, T.
 2008
 72-73 S1 p. S31-
1 p.
 artikel
626 P52 IGF-1R and LL37 – a promoting growth interaction Girnita, A.
 2010
 72-73 S1 p. S58-
1 p.
 artikel
627 P-12 IGF-1R as therapeutic target in melanoma Girnita, A.
 2008
 72-73 S1 p. S30-
1 p.
 artikel
628 P01-16 IGF receptor signaling regulates mammary epithelial cell fate and tumor susceptibility Wood, T.L.
 2012
 72-73 S1 p. S37-
1 p.
 artikel
629 P58 IGF-1 Regulates S and G2/M phases of the cell cycle in CNS progenitor cells Min, J.
 2010
 72-73 S1 p. S60-
1 p.
 artikel
630 P110 IGF signaling regulates catch-up growth and accelerated developmental timing in zebrafish embryos in response to oxygen availability Kamei, H.
 2010
 72-73 S1 p. S81-
1 p.
 artikel
631 P01-19 IGF-1 signalling enhances mitochondria activity and biogenesis in cancer cells independently of glycolytic switch Favre, C.
 2012
 72-73 S1 p. S38-
1 p.
 artikel
632 P-72 IGF systems at diagnosis in pubertal adolescent with type 1 diabetes mellitus Chisalita, S.I.
 2008
 72-73 S1 p. S48-
1 p.
 artikel
633 P-67 IGF Targeting of the IGF-IR as a potential therapeutic strategy in endometrial cancer Attias, Z.
 2008
 72-73 S1 p. S47-
1 p.
 artikel
634 P34 Increased mammary tumor lung metastases in an MKR mouse model of type 2 diabetes Ferguson, R.D.
 2010
 72-73 S1 p. S52-
1 p.
 artikel
635 P-57 Increased prevalence of acromegaly in an industrialized area of north-east of Sicily: a case-control study Ferraù, F.
 2008
 72-73 S1 p. S43-S44
2 p.
 artikel
636 P1 Influence of the d3-GH receptor and IGF1 gene polymorphisms on IGF1 and lipid profile on short and long-term treatment response in adult GH deficiency Barbosa, E.
 2010
 72-73 S1 p. S39-
1 p.
 artikel
637 P03-2 In prostate cancer cells metformin inhibits the cross-talk between membrane-initiated androgens and IGF-GR Malaguarnera, R.
 2012
 72-73 S1 p. S71-
1 p.
 artikel
638 P03-18 Insulin and IGF-I receptors in human cardiac microvascular endothelial cells; metabolic, mitogenic and anti-inflammatory effects Arnqvist, H.J.
 2012
 72-73 S1 p. S77-
1 p.
 artikel
639 P-104 Insulin and IGF-I receptors play a role in invasion of human trophoblast through MMP-9 activation Vallejo, A.F.
 2008
 72-73 S1 p. S58-
1 p.
 artikel
640 P96 Insulin and insulin-like growth factor ii induce differential endocytic sorting of the insulin receptor isoform A Morrione, A.
 2010
 72-73 S1 p. S75-
1 p.
 artikel
641 P-16 Insulin/IGF system in human pituitary tumour: clinical and patho-biological insight Cascella, T.
 2008
 72-73 S1 p. S31-
1 p.
 artikel
642 P03-3 Insulin-like growth factor I-deficiency causes skeletal defects that can be partially compensated by parathyroid hormone-related protein in mice Rodíguez-de la Rosa, L.
 2012
 72-73 S1 p. S72-
1 p.
 artikel
643 P68 Insulin-like growth factor (IGF) binding protein-3 inhibits IGF-II-stimulated IRS-1/PI-3-kinase activity and cell growth in human non-small cell lung cancer (NSCLC) cell lines Arvigo, M.
 2010
 72-73 S1 p. S63-
1 p.
 artikel
644 P03-26 Insulin-like Growth Factor-II increases de novo steroidogenesis in prostate cancer cells Lubik, A.A.
 2012
 72-73 S1 p. S80-
1 p.
 artikel
645 P-79 Insulin like growth factor 1 in prostate cancer Pidaniĉová, A.
 2008
 72-73 S1 p. S50-
1 p.
 artikel
646 P-107 Insulin-like growth factor-I prevents oxidative stress-induced apoptosis through PI3K p110a in myoblasts Matheny, W.
 2008
 72-73 S1 p. S58-S59
2 p.
 artikel
647 P28 Insulin resistance induced by GH is transient and reversible: glucose clamp studies during different ambient GH levels in GH-deficient adults Jørgensen, J.O.L.
 2010
 72-73 S1 p. S49-S50
2 p.
 artikel
648 P02-10 Insulin sensitizers modulate IGFBP-1 in EMPOWIR (Enhance the Metabolic Profile of Women with Insulin Resistance) – a randomized clinical trial (NCT00618071) of normoglycemic hyperinsulinemic women with midlife weight gain Mogul, H.R.
 2012
 72-73 S1 p. S52-
1 p.
 artikel
649 P-09 Interactions between androgen receptor and BRCA1 in regulation of IGF-I receptor gene expression in prostate cancer cells Schayek, H.
 2008
 72-73 S1 p. S29-
1 p.
 artikel
650 P02-33 Intramuscular administration of PEGylated IGF-I accelerates skeletal muscle regeneration after myotoxic injury Metzger, F.
 2012
 72-73 S1 p. S54-S55
2 p.
 artikel
651 P-54 Intravascular large B-cell lymphoma as a cause of reversible hypopituitarism Pekic, S.
 2008
 72-73 S1 p. S43-
1 p.
 artikel
652 P01-1 Investigating the mechanisms and role of IGFBP-2 nuclear translocation in cancer cells Azar, W.J.
 2012
 72-73 S1 p. S33-
1 p.
 artikel
653 P03-9 Investigation of the anti-tumorigenic effects of the M6P/IGF-II receptor Scott, C.D.
 2012
 72-73 S1 p. S74-
1 p.
 artikel
654 P43 Involvement of IGFBP-3 in the growth inhibitory effects of AZA on MDA-MB-231 breast cancer cells Zeng, L.
 2010
 72-73 S1 p. S55-
1 p.
 artikel
655 P-85 Is there a role for vitamin A on the regulation of IGF-I in children? Martinelli Jr., C.E.
 2008
 72-73 S1 p. S52-
1 p.
 artikel
656 P01-25 Ketogenic low-carb/high-fat diets lead to lower IGF-I levels and reduced longitudinal growth in rats regardless of whether the dietary fat source derives from beef tallow or soybean oil Taxeidi, C.
 2012
 72-73 S1 p. S40-
1 p.
 artikel
657 PL2 Consensus with feet of clay? Diagnostic guidelines and GH assay variability Bidlingmaier, M.
 2010
 72-73 S1 p. S1-S2
2 p.
 artikel
658 PL3 Conserved IGF-I-regulated genes and the prevention and treatment of age-related diseases Longo, V.
 2010
 72-73 S1 p. S6-
1 p.
 artikel
659 PL08 Deconstructing muscle differentiation: defining insulin-like growth factor actions in muscle development and repair Rotwein, P.
 2012
 72-73 S1 p. S17-
1 p.
 artikel
660 Plenary Lectures 2014
 72-73 S1 p. viii-
1 p.
 artikel
661 PL10 Everything in moderation: metabolic effects of GH Jorgensen, J.O.
 2008
 72-73 S1 p. S19-S20
2 p.
 artikel
662 PL03 From Galton to GWAS: what we have learned about the genetics of human stature? Visscher, P.M.
 2012
 72-73 S1 p. S6-
1 p.
 artikel
663 PL1 Genomic approaches to unraveling the complexity of GH-regulated liver sex differences Waxman, D.
 2010
 72-73 S1 p. S1-
1 p.
 artikel
664 PL7 GH and fat distribution: To be and where to be Berryman, D.
 2010
 72-73 S1 p. S16-
1 p.
 artikel
665 PL7 GH signalling Schwartz, J.
 2008
 72-73 S1 p. S17-
1 p.
 artikel
666 PL12 Growth hormone and IGF-1 in mouse models of growth and metabolism LeRoith, D.
 2012
 72-73 S1 p. S28-
1 p.
 artikel
667 PL11 Growth hormone: From starvation to obesity Klibanski, A.
 2012
 72-73 S1 p. S28-
1 p.
 artikel
668 PL3 How does the GH cell network function to build-up highly ordered GH pulses? Mollard, P.
 2008
 72-73 S1 p. S6-
1 p.
 artikel
669 P14 Lifelong serum growth hormone levels in untreated patients with Laron syndrome Laron, Z.
 2010
 72-73 S1 p. S44-
1 p.
 artikel
670 PL06 IGF-II and feto-placental growth Constância, M.
 2012
 72-73 S1 p. S12-
1 p.
 artikel
671 PL04 IGF-I, obesity and diabetes Bang, P.
 2012
 72-73 S1 p. S6-
1 p.
 artikel
672 PL2 IGF-I treatment across the lifespan Camacho-Hübner, C.
 2008
 72-73 S1 p. S2-
1 p.
 artikel
673 PL8 IGF-1 receptor in adults: What the cell-specific knockouts tell us Holzenberger, M.
 2010
 72-73 S1 p. S16-S17
2 p.
 artikel
674 PL02 IGF receptor signalling and regulation in cancer O'Connor, R.
 2012
 72-73 S1 p. S1-
1 p.
 artikel
675 PL4 Imaging insights into hypopituitarism Maghnie, M.
 2008
 72-73 S1 p. S6-
1 p.
 artikel
676 PL5 Insulin receptor isoforms in physiology and disease: impact on IGF system Belfiore, A.
 2008
 72-73 S1 p. S13-S14
2 p.
 artikel
677 PL8 Long-range chromosomal interactions in the regulation of IGF2 imprinting Hoffman, A.
 2008
 72-73 S1 p. S17-S18
2 p.
 artikel
678 PL5 Molecular mechanisms underlying IGF action Forbes, B.
 2010
 72-73 S1 p. S11-S12
2 p.
 artikel
679 PL10 Neuroprotection and plasticity in the brain related to GH & IGF-I Aberg, D.
 2012
 72-73 S1 p. S23-
1 p.
 artikel
680 PL1 New GH-related molecules with therapeutic potential Ross, R.
 2008
 72-73 S1 p. S2-
1 p.
 artikel
681 P02-20 Local overexpression of growth hormone and GH/IGF-1-associated effects in the adult hippocampus Aberg, M.
 2012
 72-73 S1 p. S60-
1 p.
 artikel
682 P15 Long-term administration of hGH or IGF-I increase body adiposity and serum cholesterol Laron, Z.
 2010
 72-73 S1 p. S44-S45
2 p.
 artikel
683 P02-49 Long-term outcomes of Pegvisomant (Somavert®) monotherapy: Cross-sectional observations from ACROSTUDY van der Lely, A.J.
 2012
 72-73 S1 p. S68-
1 p.
 artikel
684 P02-4 Long term treatment of rh-IGF-1 and high dose insulin of a Japanese patient with insulin receptor defect Tajima, T.
 2012
 72-73 S1 p. S50-
1 p.
 artikel
685 P79 Low dose insulin-like growth factor-1 has potent early anti-apoptotic and signaling effects, and long-term structural, remodeling, and functional benefits post ischemia-reperfusion O'Sullivan, J.F.
 2010
 72-73 S1 p. S67-
1 p.
 artikel
686 P02-8 Low IGF-1 levels are associated with and predictive for the incidence of anxiety disorders in primary care patients (DETECT-cohort) and the general population (SHIP-cohort) Sievers, C.
 2012
 72-73 S1 p. S51-
1 p.
 artikel
687 P01-34 Low-intensity pulsed ultrasounds produces and increase of IGF-I gene expression during fibula bone repair in rats Marrero, I.
 2012
 72-73 S1 p. S44-
1 p.
 artikel
688 PL05 Prolactin and tumorigenesis Goffin, V.
 2012
 72-73 S1 p. S12-
1 p.
 artikel
689 PL9 Regulation of pancreatic endocrine function by IGF and insulin signalling Accili, D.
 2008
 72-73 S1 p. S19-
1 p.
 artikel
690 PL4 Role of GH/IGF-I in adaptation of matrix in skeletal muscle and tendon to exercise Kjær, M.
 2010
 72-73 S1 p. S7-
1 p.
 artikel
691 PL9 Strategies for identifying genes involved in cell lineage specification and expansion: from stem cell to hormone producing cells Camper, S.
 2010
 72-73 S1 p. S22-
1 p.
 artikel
692 PL6 Targeting the IGF pathway in breast cancer Lee, A.
 2010
 72-73 S1 p. S12-
1 p.
 artikel
693 PL10 The curious case of ghrelin Korbonits, M.
 2010
 72-73 S1 p. S22-
1 p.
 artikel
694 PL07 The essential role of GH/IGF-I in the liver Takahashi, Y.
 2012
 72-73 S1 p. S17-
1 p.
 artikel
695 PL6 The role of the IGF-IR in cancer: initiation and progression or therapeutic target? Plymate, S.
 2008
 72-73 S1 p. S14-
1 p.
 artikel
696 PL12 Twenty years of efficacy and safety information with recombinant human IGF-I therapy: How will our clinical experience alter the approach to the treatment of short stature? Backeljauw, P.
 2010
 72-73 S1 p. S27-S28
2 p.
 artikel
697 PL01 Two years in GH Ho, K.
 2012
 72-73 S1 p. S1-
1 p.
 artikel
698 PL09 Two years in IGF Rosenfeld, R.G.
 2012
 72-73 S1 p. S22-S23
2 p.
 artikel
699 PL11 Who needs IGFs? IGFBP-3 activates growth-stimulatory pathways Baxter, R.
 2010
 72-73 S1 p. S27-
1 p.
 artikel
700 P3 Macimorelin, an oral ghrelin-mimetic GH secretagogue, as a potential diagnostic test for adult GH deficiency Biller, B.M.K.
 2010
 72-73 S1 p. S40-
1 p.
 artikel
701 P01-13 Mechanisms behind nuclear translocation of the IGF-1R Sjostrom, S.
 2012
 72-73 S1 p. S36-
1 p.
 artikel
702 P60 Mechanisms for glutamate exicitotoxicity and IGF-I survival in late OPCs Simonishvili, S.
 2010
 72-73 S1 p. S60-S61
2 p.
 artikel
703 P17 Mental functioning improvement on growth hormone replacement in growth hormone deficient patients after traumatic brain injury Doknic, M.
 2010
 72-73 S1 p. S45-
1 p.
 artikel
704 P-32 Metabolic complications in patients with adult growth hormone deficiency Kurimoto, M.
 2008
 72-73 S1 p. S36-
1 p.
 artikel
705 P-42 Metabolic profile of patients with idiopatic short stature (ISS) according to GH and IGF-I status Martinelli, C.
 2008
 72-73 S1 p. S39-
1 p.
 artikel
706 P-28 Metabolic status at baseline and after 3 years of GH treatment in patients with Cushing's disease and non-functioning adenomas: a hypopituitary control and complications study analysis Webb, S.
 2008
 72-73 S1 p. S35-
1 p.
 artikel
707 P42 Metformin displays antiproliferative activities in endometrial cancer cells via interaction with the IGF-1R signaling axis Werner, H.
 2010
 72-73 S1 p. S54-S55
2 p.
 artikel
708 P-10 Mitogenic activity and signaling pathways elicited by long-acting insulin analogues Glargine and Detemir in colon cancer derived cell lines Weinstein, D.
 2008
 72-73 S1 p. S29-S30
2 p.
 artikel
709 P-63 Molecular mechanisms underlying the anti-inflammatory action of IGF-I in astrocytes Fernández, A.M.
 2008
 72-73 S1 p. S45-
1 p.
 artikel
710 P03-44 MR imaging features of growth hormone-producing pituitary adenoma Fukuda, I.
 2012
 72-73 S1 p. S87-
1 p.
 artikel
711 P-75 Muscle expression of MGF, IGF-IEa and myostatin in intact and hypophysectomized rats: effects of rhGH testosterone alone or combined Bonomo, S.M.
 2008
 72-73 S1 p. S49-
1 p.
 artikel
712 P75 Mutated IGF-I receptor (D1105E) extinguish autophosphorylation: A family of short stature born intrauterine growth retardation bearing a novel missense mutation of the IGF-I receptor Kawashima, Y.
 2010
 72-73 S1 p. S66-
1 p.
 artikel
713 P03-41 Natural history of congenital isolated growth hormone deficiency Laron, Z.
 2012
 72-73 S1 p. S86-
1 p.
 artikel
714 P-101 Neuronal activity regulates serum IGF-I input to the brain Nishijima, T.
 2008
 72-73 S1 p. S57-
1 p.
 artikel
715 P69 Neutrophil-derived azurocidin proteolyses IGF binding protein-1, -2 and -4 Brandt, K.
 2010
 72-73 S1 p. S63-
1 p.
 artikel
716 P74 New IGF-1 normative data for healthy, Contemporary US children Chandler, D.W.
 2010
 72-73 S1 p. S65-
1 p.
 artikel
717 P02-41 Non alcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-1 levels Fusco, A.
 2012
 72-73 S1 p. S64-S65
2 p.
 artikel
718 P12 Norditropin increases lean muscle, reduces fat mass and normalizes height in children with Prader-Willi Syndrome Kappelgaard, A.-M.
 2010
 72-73 S1 p. S43-
1 p.
 artikel
719 PO3-14: Activated STAT3 as a possible resistance mechanism to the anti-tumour effects of an anti-IGF-II neutralising antibody in hepatocellular carcinoma Greenall, S.A.
 2014
 72-73 S1 p. S34-
1 p.
 artikel
720 PO3-13: ADLib® system: a versatile antibody discovery platform Hashimoto, S.
 2014
 72-73 S1 p. S34-
1 p.
 artikel
721 PO4-1: Alpha-fetoprotein at birth: an early marker of circulating IGF-I in preterm infants Kistner, A.
 2014
 72-73 S1 p. S49-
1 p.
 artikel
722 PO3-16: Altered mouse adipose tissue IGF-1 expression influences glucose control Trost, J.
 2014
 72-73 S1 p. S35-
1 p.
 artikel
723 PO1-1: Analysis of chimeric mice using growth hormone receptor gene disrupted (GHRKO) derived bone-marrow to investigate the role of GH signaling in the infiltration of proinflammatory macrophages in adipose tissue Herpy, J.
 2014
 72-73 S1 p. S26-
1 p.
 artikel
724 PO2-2: An evaluation of the safety and usability of FlexPro® 30 mg/3 mL, for the delivery of Norditropin® in patients requiring growth hormone (GH) therapy Kappelgaard, A.-M.
 2014
 72-73 S1 p. S39-
1 p.
 artikel
725 PO2-7: Assessing the impact of storage flexibility on daily life for patients and caregivers taking/administering growth hormone (GH) Kappelgaard, A.-M.
 2014
 72-73 S1 p. S41-
1 p.
 artikel
726 PO2-25: Assessment of hydration based on bioelectrical impedance analysis (BIA) and arm muscle area (AMA) in treatment-naïve adult patients with growth hormone deficiency (GHD) Jørgensen, J.O.L.
 2014
 72-73 S1 p. S47-
1 p.
 artikel
727 PO2-6: Autocrine human growth hormone (hGH) promotes metabolic reprogramming in breast cancer cells to adapt to available glucose Banerjee, A.
 2014
 72-73 S1 p. S41-
1 p.
 artikel
728 PO3-12: Balancing the IGF-1R-Mdm2-p53 axis as novel therapeutic strategy in skin melanoma Girnita, A.
 2014
 72-73 S1 p. S33-
1 p.
 artikel
729 P-03 Obestatin and ghrelin function in ovarian cancer cell lines, Walpole, C.
 2008
 72-73 S1 p. S27-
1 p.
 artikel
730 PO4-4: Cerebrospinal fluid and serum levels of growth hormone (GH), insulin-like-growth factor-I (IGF-1), insulin-like growth factor binding protein -3 (IGFBP-3) and ghrelin in patients with bacterial and tuberculous meningitis Akinci, A.
 2014
 72-73 S1 p. S50-
1 p.
 artikel
731 PO5-1: Clinical relevance of serum prolactin level in perimenopausal women with metabolic syndrome Pchelin, I.
 2014
 72-73 S1 p. S52-
1 p.
 artikel
732 PO4-9: Complex tissue-specific epigenotypes in Russell Silver syndrome with 11p15 ICR1 hypomethylation: major consequences for the diagnosis Azzi, S.
 2014
 72-73 S1 p. S51-S52
2 p.
 artikel
733 PO3-10: Constitutive IRS1 expression causes cell competition, leading to defect in myogenic differentiation Hakuno, F.
 2014
 72-73 S1 p. S33-
1 p.
 artikel
734 PO3-5: Developing predictive determinants of IGF/INS targeted therapies in ovarian cancer patient tumors and primary tumorgrafts Becker, M.
 2014
 72-73 S1 p. S31-
1 p.
 artikel
735 PO2-12: Development and characterization of manufacturing process of MOD-4023, a long acting human growth hormon to support clinical and commercial supply Hershkovitz, O.
 2014
 72-73 S1 p. S42-S43
2 p.
 artikel
736 PO3-9: Effects of endurance training on somatic growth in a rat model of chronic kidney disease (CKD) Troib, A.
 2014
 72-73 S1 p. S32-
1 p.
 artikel
737 PO2-24: Elevated spontaneous trough GH levels are associated with Lipoprotein (a) in short prepubertal children with high waist-hip ratio Decker, R.
 2014
 72-73 S1 p. S46-
1 p.
 artikel
738 PO2-11: Evidence for truncated somatostatin receptor 5 modulation of therapy response to somatostatin analogues in two patients with acromegaly and severe headache Marina, D.
 2014
 72-73 S1 p. S42-
1 p.
 artikel
739 PO4-7: Functional selectivity of the insulin-like growth factor type 1 receptor (IGF-1R) signaling: therapeutic implications for cancer treatment Girnita, L.
 2014
 72-73 S1 p. S51-
1 p.
 artikel
740 PO2-14: Genetic markers of insulin resistance are associated with growth hormone response in short SGA children - the North European SGA study (NESGAS) Jensen, R.B.
 2014
 72-73 S1 p. S43-
1 p.
 artikel
741 PO2-23: Growth and puberty of children with congenital isolated growth hormone deficiency Smuel, K.
 2014
 72-73 S1 p. S46-
1 p.
 artikel
742 PO3-7: Growth hormone addition to medium in HepG2 cell culture: influence on IGF-I and IGF-II production Knaack, H.
 2014
 72-73 S1 p. S32-
1 p.
 artikel
743 PO2-21: Growth hormone deficiency amongst nasopharyngeal cancer survivors Ratnasingam, J.
 2014
 72-73 S1 p. S45-
1 p.
 artikel
744 PO2-19: Growth hormone therapy in a child with Kearns Sayre syndrome and chronic kidney disease Sng, A.
 2014
 72-73 S1 p. S44-S45
2 p.
 artikel
745 PO2-10: Growth hormone treatment: case studies in Dr Soetomo Hospital Rochmah, N.
 2014
 72-73 S1 p. S42-
1 p.
 artikel
746 PO2-9: Growth without growth hormone Rochmah, N.
 2014
 72-73 S1 p. S41-S42
2 p.
 artikel
747 PO2-13: Human growth hormone and human prolactin possess autocrine roles in hepatocellular carcinoma Zhang, M.
 2014
 72-73 S1 p. S43-
1 p.
 artikel
748 PO3-17: Hypermethylation and hypomethylation of IGF-II DMRO (Insulin like growth factors-II Differentially Methylated Region) correlated to increased or decreased expression of IGF-II in breast cancer cells and paired breast tissues of African American and Caucasian breast cancer patients Radhakrishnan, V.K.
 2014
 72-73 S1 p. S35-
1 p.
 artikel
749 PO2-16: IGF-1 as nutritional marker Kim, J.H.
 2014
 72-73 S1 p. S44-
1 p.
 artikel
750 PO3-19: IGF-1 receptor C terminal tail phosphorylation on Y1250 in cancer cells O Shea, S.P.
 2014
 72-73 S1 p. S35-S36
2 p.
 artikel
751 PO3-4: IGF-1-regulated PDLIM2 protein is required for epithelial to mesenchymal transition (EMT) and transcription factor stability Cox, O.T.
 2014
 72-73 S1 p. S31-
1 p.
 artikel
752 PO4-5: Insulin like growth factor-1 therapy in five patients with growth hormone insensitivity Ersoy, B.
 2014
 72-73 S1 p. S50-
1 p.
 artikel
753 PO2-15: Insulin tolerance test and GHRH plus arginine in the reassessment of pituitary function at adult height achievement Di Iorgi, N.
 2014
 72-73 S1 p. S44-
1 p.
 artikel
754 PO3-18: Lipopolysaccharide (LPS) treatment increased the protein levels of GKAP42 (42-kDa cGMP-dependent protein kinase anchoring protein) followed by inhibition of insulinmediated glucose transporter (GLUT) 4 translocation to the plasma membrane and glucose uptake in adipocytes Yu, B.-C.
 2014
 72-73 S1 p. S35-
1 p.
 artikel
755 PO3-2: Modulation of IGFBP1 protein expression by metformin Ansurudeen, I.
 2014
 72-73 S1 p. S30-
1 p.
 artikel
756 PO3-1: Molecular, biochemical, histological, and phylogenetic characterizations of insulin-like peptides and insulin/insulinlike growth factor (IGF)-I receptors in rotifers Ozaki, Y.
 2014
 72-73 S1 p. S30-
1 p.
 artikel
757 PO2-3: Multiple doses of a reversible albumin-binding growth hormone derivative demonstrate no differences in PK and PD between Japanese and non-Asian subjects Højby Rasmussen, M.
 2014
 72-73 S1 p. S40-
1 p.
 artikel
758 P03-37 Once-weekly, CTP-modified hGH (MOD-4023) is effective in growth hormone deficient adults: A phase II, dose and frequency finding study Goth, M.I.
 2012
 72-73 S1 p. S84-S85
2 p.
 artikel
759 PO2-26: Pharmacokinetic (PK) and pharmacodynamic (PD) modeling of MOD-4023 (a long-acting hGH-CTP) in adults and growth hormone (GH)-deficient children Fisher, D.
 2014
 72-73 S1 p. S47-
1 p.
 artikel
760 PO3-11: Porphyra yezoensis peptide stimulates the proliferation of IEC-6 cells by activating the insulin-like growth factor-I receptor signaling pathway Nam, T.-J.
 2014
 72-73 S1 p. S33-
1 p.
 artikel
761 PO2-4: Pregnancy in acromegaly patients treated with pegvisomant Van der Lely, A.J.
 2014
 72-73 S1 p. S40-
1 p.
 artikel
762 P02-44 Oral octreotide absorption in human subjects: Comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression Tuvia, S.
 2012
 72-73 S1 p. S66-
1 p.
 artikel
763 PO3-15: Regulation of IGF-1 at the transcription level by IGFBP-1 Ansurudeen, I.
 2014
 72-73 S1 p. S34-
1 p.
 artikel
764 PO2-20: Safety evaluation of long-term recombinant growth hormone (rGH) treatment in paediatric patients: interim analysis of NordiNet® International Outcome Study (IOS) Sävendahl, L.
 2014
 72-73 S1 p. S45-
1 p.
 artikel
765 PO3-6: Serum concentrations of IGF-I and IGF-II proceed in a reciprocal manner during a physiological cycle and maternal IGFBP-4 concentration was lower in pregnant than in not pregnant dairy heifers during early pregnancy Meyerholz, M.
 2014
 72-73 S1 p. S31-
1 p.
 artikel
766 PO4-6: Serum levels of IGF-I and IGFBP-1 in Indian diabetic population Tekle, M.
 2014
 72-73 S1 p. S50-S51
2 p.
 artikel
767 PO4-3: Serum levels of insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein 3 (IGFBP-3) in women with cervical cancer Cho, D.H.
 2014
 72-73 S1 p. S50-
1 p.
 artikel
768 PO5-2: Serum prolactin level in chronic kidney disease Vasilkova, O.
 2014
 72-73 S1 p. S52-
1 p.
 artikel
769 PO2-5: Severe headache relieved by short-acting somatostatin analogue in a patient with Acromegaly resistant to longacting somatostatin analogues Hoybye, C.
 2014
 72-73 S1 p. S40-
1 p.
 artikel
770 PO1-5: Socs 2 plays no major role in the increased expression of fibrotic genes in the remnant kidney Assadi, M.H.
 2014
 72-73 S1 p. S26-S27
2 p.
 artikel
771 PO2-17: Soluble alpha-Klotho and vitamin D in acromegaly Bolanowski, M.
 2014
 72-73 S1 p. S44-
1 p.
 artikel
772 PO2-8: Specific measurement of human growth hormone oligomers in blood and its possible clinical application Wu, Z.
 2014
 72-73 S1 p. S41-
1 p.
 artikel
773 Poster Exhibition 2016
 72-73 S1 p. S34-S50
17 p.
 artikel
774 PO4-8: Subclinical hypothyroidism is associated with low IGF-I levels and decreased growth velocity Bellini, H.
 2014
 72-73 S1 p. S51-
1 p.
 artikel
775 Potential use of growth hormonereceptor antagonist in the treatment of diabetic kidney disease Flyvbjerg, Allan
 2001
 72-73 S1 p. S115-S119
5 p.
 artikel
776 PO3-3: The hepatic expression of GHR and SOCS2 mRNA is increased before ovulation during the follicular phase in dairy cattle Mense, K.
 2014
 72-73 S1 p. S30-S31
2 p.
 artikel
777 PO2-1: The pathogenesis of anti-PIT-1 antibody syndrome - the involvement of PIT-1-reactive cytotoxic T lymphocytes Bando, H.
 2014
 72-73 S1 p. S39-
1 p.
 artikel
778 PO3-8: Understanding and targeting the IGFBP-3/IGFBP-3R system in obesity related disorders: IGFBP-3R agonists as preventive and therapeutic interventions for obesity-induced IR and T2DM Cai, Q.
 2014
 72-73 S1 p. S32-
1 p.
 artikel
779 PO2-22: Usability and safety of FlexPro® PenMate®, a growth hormone (GH) injection system, in patients, caregivers and healthcare professionals Wen, Y.
 2014
 72-73 S1 p. S46-
1 p.
 artikel
780 PO4-2: Variations in growth in relation to IGF-I levels in children born very preterm and target height influences from birth to 3-years of age Kistner, A.
 2014
 72-73 S1 p. S49-S50
2 p.
 artikel
781 P13 Patient Perception of injection pain and anxiety: a comparison of two pen injection device systems, Norditropin® FlexPro® with FlexPro® PenMate®, and Norditropin NordiFlex® with NordiFlex PenMate® Kappelgaard, A.-M.
 2010
 72-73 S1 p. S44-
1 p.
 artikel
782 P-69 Patients with liver cirrhosis have higher levels of bioactive IGF-I in ascites than in serum Jeyaratnaganthan, N.
 2008
 72-73 S1 p. S47-
1 p.
 artikel
783 P01-48 Pediatric patients with Prader-Willi syndrome are responders to growth hormone treatment: Analysis of 3-year data from the ANSWER Program Cohen, P.
 2012
 72-73 S1 p. S49-
1 p.
 artikel
784 P2 Pegvisomant therapy in acromegaly: a multicenter Bianchi, A.
 2010
 72-73 S1 p. S39-
1 p.
 artikel
785 P19 PenMate evaluation in growth hormone (GH) treated children injecting themselves in comparison with GH treated children injected by their parents Hokken-Koelega, A.
 2010
 72-73 S1 p. S46-S47
2 p.
 artikel
786 P-70 Peripheral sensory neuropathy in type 2 diabetes is associated with increased IGFBP-1 Kärvestedt, L.
 2008
 72-73 S1 p. S47-S48
2 p.
 artikel
787 P20 Pharmacokinetic-pharmacodynamic model for a pegylated, long-acting human growth hormone developed for once-weekly administration Rasmussen, M.H.
 2010
 72-73 S1 p. S47-
1 p.
 artikel
788 P-58 Pharmacokinetics and pharmacodynamics of a single injection of a pegylated long-acting recombinant growth hormone Bysted, B.
 2008
 72-73 S1 p. S44-
1 p.
 artikel
789 P02-18 Pharmacological characterisation of NNC0195–0092, a long-acting growth hormone derivative Thygesen, P.
 2012
 72-73 S1 p. S59-S60
2 p.
 artikel
790 P03-25 Pharmacological properties of BI 836845, a fully human IGF ligand neutralizing antibody Hofmann, M.H.
 2012
 72-73 S1 p. S80-
1 p.
 artikel
791 P67 PI 3-kinase activation through c-Src-dependent tyrosine phosphorylation of PITKAP/XB130, a novel binding partner of a PI 3-kinase p85 regulatory subunit, plays novel roles in priming cells to IGF Yamanaka, D.
 2010
 72-73 S1 p. S62-S63
2 p.
 artikel
792 P27 Pituitary choriocarcinoma in an adolescent: tumor-derived CG and GHv delay presentation Wildi-Runge, S.
 2010
 72-73 S1 p. S49-
1 p.
 artikel
793 P-56 Pituitary function in young ischemic stroke patient: preliminary data Di Somma, C.
 2008
 72-73 S1 p. S43-
1 p.
 artikel
794 P81 Pituitary insufficiency in the acute phase of traumatic brain injury or subarachnoid hemorrhage: a prospective study Sigurjonsson, P.
 2010
 72-73 S1 p. S68-
1 p.
 artikel
795 P88 Plasma levels of insulin-like growth factor-I, insulin-like growth factor binding protein-1, coenzyme Q10 and vitamin E in Kenyan populations Tekle, M.
 2010
 72-73 S1 p. S71-
1 p.
 artikel
796 P01-39 Polymorphisms in genes related to lipid metabolism contribute to individual differences in serum lipid profile of growth hormone deficient (GHD) adults Barbosa, E.J.
 2012
 72-73 S1 p. S46-
1 p.
 artikel
797 P82 Positive clinical results with vitronectin: IGF complexes for the treatment of chronic wounds Upton, Z.
 2010
 72-73 S1 p. S68-S69
2 p.
 artikel
798 P77 Postnatal serum IGF-1 deficiency is associated with bronchopulmonary dysplasia Lofqvist, C.
 2010
 72-73 S1 p. S66-S67
2 p.
 artikel
799 P01-38 Post-stroke inflammatory response may influence pituitary function in patients with brain ischemic and hemorrhagic injury Bondanelli, M.
 2012
 72-73 S1 p. S45-
1 p.
 artikel
800 P03-14 Posttranslational modifications of the insulin-like growth factor-binding protein 3 in patients with non-insulin dependent diabetes mellitus and their effect on ligand binding Nedic, O.
 2012
 72-73 S1 p. S76-
1 p.
 artikel
801 P03-13 Preclinical effectiveness of metformin in Ewing sarcoma Garofalo, C.
 2012
 72-73 S1 p. S75-S76
2 p.
 artikel
802 P02-54 Prediabetes in adult growth hormone deficiency is associated with a substantial reduction in serum and adipose tissue expression levels of zinc-α2-glycoprotein Balaz, M.
 2012
 72-73 S1 p. S70-
1 p.
 artikel
803 P-97 Predictive value of insulin like growth factor II (IGF-II) mRNA expression in breast cancer (BC) Fiore, E.
 2008
 72-73 S1 p. S55-
1 p.
 artikel
804 P7 Predictors of pituitary dysfunction in patients surviving ischemic stroke Bondanelli, M.
 2010
 72-73 S1 p. S41-
1 p.
 artikel
805 P-35 Preference of growth hormone provocative test in diagnosing GH deficiency in clinical practice — data from Japanese HypoCCS study Shimatsu, A.
 2008
 72-73 S1 p. S37-
1 p.
 artikel
806 P100 Prevalence of IGF-1 deficiency (IGFD) among ISS patients Lazareva, O.
 2010
 72-73 S1 p. S77-
1 p.
 artikel
807 P-109 Production of mouse growth hormone antagonist (G118K) Gosney, E.
 2008
 72-73 S1 p. S59-
1 p.
 artikel
808 P01-33 Proinsulin may exert biological effects in MCF-7 human cancer cells through both isoform A of the insulin receptor and atypical IGF-I receptors Malaguarnera, R.
 2012
 72-73 S1 p. S43-S44
2 p.
 artikel
809 P40 Proinsulin mediates proliferative effects by activating the isoform a of the insulin receptor Sacco, A.
 2010
 72-73 S1 p. S54-
1 p.
 artikel
810 P02-3 Prolactinomas in two patients with pituitary developmental gene mutations Doknic, M.
 2012
 72-73 S1 p. S58-S59
2 p.
 artikel
811 P76 Prolactin serum levels in untreated and IGF-I treated patients with Laron syndrome are elevated and suppressed by IGF-I treatment Laron, Z.
 2010
 72-73 S1 p. S66-
1 p.
 artikel
812 P-100 Promoter haplotype in the insulin-like growth factor-binding protein-3 gene: correlation with serum levels, growth and response to growth hormone treatment in short children born small for gestational age van der Kaay, D.
 2008
 72-73 S1 p. S56-S57
2 p.
 artikel
813 P-99 Promoter polymorphism in the insulin-like growth factor-binding protein-1 gene: correlation with serum IGFBP-1 levels and insulin levels in short children born small for gestational age van der Kaay, D.
 2008
 72-73 S1 p. S56-
1 p.
 artikel
814 P-38 Prospective comparison of the Glucagon Stimulation Test (GST) with the Insulin Tolerance Test (ITT) in patients following pituitary surgery Berg, C.
 2008
 72-73 S1 p. S38-
1 p.
 artikel
815 P02-29 Quantification of brown adipocyte markers in white adipose tissues of mice with altered Growth Hormone action Vesel, C.B.
 2012
 72-73 S1 p. S63-S64
2 p.
 artikel
816 P03-11 Quantifying insulin receptor isoform expression in FFPE breast tumors Harrington, S.
 2012
 72-73 S1 p. S75-
1 p.
 artikel
817 P01-43 Radiotherapy and growth hormone replacement therapy in growth hormone deficient adults with craniopharyngioma: Preliminary data from the Dutch National Registry of Growth Hormone Treatment in Adults van Varsseveld, N.C.
 2012
 72-73 S1 p. S47-S48
2 p.
 artikel
818 P89 Recombinant human GH stimulates IGF-I mRNA expression and secretion in hepatocytes of C57BL/6 mice in vitro, but not in vivo Bielohuby, M.
 2010
 72-73 S1 p. S72-
1 p.
 artikel
819 P02-55 Reduced epiphyseal growth plate GHR signaling in a chronic kidney disease rat model of growth retardation Troib, A.
 2012
 72-73 S1 p. S70-
1 p.
 artikel
820 P35 Reduced serum IGF-1 levels do not affect insulin-mediated mammary tumor progression in type 2 diabetes Fierz, Y.C.
 2010
 72-73 S1 p. S52-
1 p.
 artikel
821 P02-11 Regulation of insulin-like growth factor binding protein-6: An inhibitor of fibroblast proliferation and myofibroblast differentiation in Dupuytren's Disease Raykha, C.
 2012
 72-73 S1 p. S52-
1 p.
 artikel
822 P101 Regulation of osteoclast differentiation by the IGF binding protein IGFBP-2 Maile, L.A.
 2010
 72-73 S1 p. S77-
1 p.
 artikel
823 P-62 Regulation of suppressor of cytokine signalling-2 gene expression in liver and kidney by estradiol, growth hormone and thyroid hormone interaction Santana-Farré, R.
 2008
 72-73 S1 p. S45-
1 p.
 artikel
824 P-21 Relationship between IGF-I levels and peripheral nerve enlargement in acromegaly Resmini, E.
 2008
 72-73 S1 p. S33-
1 p.
 artikel
825 P-77 Relationships between serum insulin-like growth factor-I levels, blood pressure and glucose tolerance: an observational, exploratory study in 404 subjects Colao, A.
 2008
 72-73 S1 p. S49-S50
2 p.
 artikel
826 P25 Response of growth hormone release compared betwen growth hormone-releasing peptide-2 test and glucagon stimulation test in adults Tanimoto, K.
 2010
 72-73 S1 p. S48-
1 p.
 artikel
827 P107 rhIGF-1 therapy for growth failure and IGF-1 deficiency in Congenital Disorder of Glycosylation Ia Miller, B.S.
 2010
 72-73 S1 p. S79-S80
2 p.
 artikel
828 Program at a Glance 2010
 72-73 S1 p. vi-
1 p.
 artikel
829 Program at a glance 2008
 72-73 S1 p. vi-
1 p.
 artikel
830 Program at a Glance 2014
 72-73 S1 p. vii-
1 p.
 artikel
831 Program at a Glance 2012
 72-73 S1 p. vi-
1 p.
 artikel
832 P66 Role of IGF-1R signaling in uveal melanoma Worrall, C.
 2010
 72-73 S1 p. S62-
1 p.
 artikel
833 P02-34 Role of Igf-1 signaling in statin-induced myotoxicity Bonifacio, A.
 2012
 72-73 S1 p. S55-
1 p.
 artikel
834 P-88 Role of oxidative stress on the regulation of IGFBP-1 mRNA in protein-deprived rat liver Takenaka, A.
 2008
 72-73 S1 p. S52-S53
2 p.
 artikel
835 P-18 Russell-Silver Syndrome: clinical scoring system and molecular investigations on a large series of patients Netchine, I.
 2008
 72-73 S1 p. S32-
1 p.
 artikel
836 P01-10 Selective recruitment of G protein coupled receptor kinases (GRKs) controls trafficking of Insulin-like Growth Factor-1 Receptor (IGF-1R) Zheng, H.
 2012
 72-73 S1 p. S36-
1 p.
 artikel
837 P02-6 Serum IGF-I in breast cancer patients – a comparative study of IGF-I measurements by both automated methodology (IDS iSYS) as well as gel chromatography at low pH Espelund, U.
 2012
 72-73 S1 p. S50-S51
2 p.
 artikel
838 P02-13 Serum IGF-I levels in children with idiopathic short stature (ISS) during treatment with Somatropin in a prospective, longitudinal non-randomised, open, phase II study Dörr, H.G.
 2012
 72-73 S1 p. S53-
1 p.
 artikel
839 P02-12 Serum insulin-like growth factor binding protein-3 (IGFBP-3) levels are correlated with glycemic control and lipid metabolism in adolescents with type 2 diabetes Lee, D.-Y.
 2012
 72-73 S1 p. S53-
1 p.
 artikel
840 P-103 Serum levels of IGF-1, IGFBP-1, CoQ10 and Vitamin E in four female populations from Poland, Serbia, and Sweden Tekle, M.
 2008
 72-73 S1 p. S57-
1 p.
 artikel
841 P41 Serum levels of insulin-like growth factor-I and oncogenic human papillomavirus natural history Serrano, M.-L.
 2010
 72-73 S1 p. S54-
1 p.
 artikel
842 P80 Serum markers of response in a neo-adjuvant clinical trial of the IGF-IR mabA12 in prostate cancer Plymate, S.
 2010
 72-73 S1 p. S68-
1 p.
 artikel
843 P6 Serum protein changes in acromegalic individuals following transsphenoidal surgery Cruz-Topete, D.
 2010
 72-73 S1 p. S41-
1 p.
 artikel
844 P02-35 Severe reductions of brain weights and behavioral changes in transgenic mice overexpressing mutated IGFBP-2 lacking a heparin binding domain Schindler, N.
 2012
 72-73 S1 p. S55-S56
2 p.
 artikel
845 P02-2 Sex-specific associations of serum prolactin concentrations with cardiac remodeling: Longitudinal results from the study of health Pomerania (SHIP) Haring, R.
 2012
 72-73 S1 p. S58-
1 p.
 artikel
846 P21 Sheehan's syndrome in modern times Kristjansdottir, H.L.
 2010
 72-73 S1 p. S47-
1 p.
 artikel
847 P-04 Short-interfering RNA for targeting IGFs in tumour cells Durfort, T.
 2008
 72-73 S1 p. S28-
1 p.
 artikel
848 P99 SHOX gene variants: growth hormone/IGF-1 status and response to growth hormone treatment Klein, M.L.
 2010
 72-73 S1 p. S76-S77
2 p.
 artikel
849 P-60 Signaling differences in the A and B isoforms of the insulin receptor in 32D cells stimulated by either insulin or IGF-II in the presence of IRS-3 Cassarino, M.F.
 2008
 72-73 S1 p. S44-S45
2 p.
 artikel
850 P36 Silencing of IGF-IR and IGF-I induce antitumoral immune response in breast cancer model Durfort, T.
 2010
 72-73 S1 p. S52-S53
2 p.
 artikel
851 P02-17 Sirt1 negatively regulates IGF-I production by growth hormone via deacetylation of Stat5 in liver Yamamoto, M.
 2012
 72-73 S1 p. S59-
1 p.
 artikel
852 P01-50 Smoking, body composition and bone health in adult patients with Growth Hormone (GH)-treated GH deficiency – an observational study Klefter, O.N.
 2012
 72-73 S1 p. S49-S50
2 p.
 artikel
853 P02-22 Sodium Butyrate treatment increases Growth Hormone (GH) secretion in autosomal dominant GH deficiency caused by the splice site mutations Miletta, M.C.
 2012
 72-73 S1 p. S61-
1 p.
 artikel
854 P-05 Specific targeting of IGF-I and IGF-IR genes by antigene nucleic acids Oussedik, K.
 2008
 72-73 S1 p. S28-
1 p.
 artikel
855 P02-37 Structural and functional alterations in skeletal muscle of IGFBP-4 KO mice Zhao, X.
 2012
 72-73 S1 p. S56-
1 p.
 artikel
856 P03-6 Structural studies of insulin-like growth factor I interacting with the type 1 Insulin-like growth factor receptor in the presence of inhibiting or enhancing monoclonal anti-bodies Thomas, D.
 2012
 72-73 S1 p. S73-
1 p.
 artikel
857 P03-28 Structural studies of the type 1 insulin-like growth factor receptor in apo- and ligand-bound forms by cryo-electron microscopy Kong, G.K.W.
 2012
 72-73 S1 p. S81-
1 p.
 artikel
858 P46 Studies on the bivalent interaction of IGF-II with the insulin and type 1 IGF receptors Alvino, C.L.
 2010
 72-73 S1 p. S56-
1 p.
 artikel
859 P-83 Study of two IGF-1R gene expression variants Steunou, V.
 2008
 72-73 S1 p. S51-
1 p.
 artikel
860 P03-46 Successful pregnancy during use of octreotide and pegvisomant in an acromegalic patient van der Klauw, M.M.
 2012
 72-73 S1 p. S88-
1 p.
 artikel
861 P03-38 Suppressor of cytokine signaling 2 missense mutation identified in a patient with gigantism without growth hormone producing pituitary adenoma Suda, K.
 2012
 72-73 S1 p. S85-
1 p.
 artikel
862 P03-36 Sustained effect of Insulin-Like Growth Factor-I (IGF-I)-based dosing of Growth Hormone Treatment (GHT) in children: Comparative analysis of data from a randomized trial and the ANSWER Program® Cohen, P.
 2012
 72-73 S1 p. S84-
1 p.
 artikel
863 P-50 Sweat secretion in obese subjects with hyposomatotropism Rasmussen, M. Højby
 2008
 72-73 S1 p. S41-S42
2 p.
 artikel
864 P02-43 Tailored GH treatment in paediatric settings – it is time for a paradigm-shift based on two randomized trials Dahlgren, J.
 2012
 72-73 S1 p. S65-
1 p.
 artikel
865 P33 Targeting of the IGF-IR as a potential therapeutic strategy in endometrial cancer Attias-Geva, Z.
 2010
 72-73 S1 p. S51-
1 p.
 artikel
866 P-22 Ten-year growth hormone (GH) replacement normalizes muscle strength in GH deficient adults Götherström, G.
 2008
 72-73 S1 p. S33-
1 p.
 artikel
867 P02-5 The association of serum insulin-like growth factor-I with metabolic syndrome in older people: A population-based study van Bunderen, C.C.
 2012
 72-73 S1 p. S50-
1 p.
 artikel
868 P02-1 The association of serum prolactin concentration with inflammatory biomarkers – cross-sectional findings from the population-based Study of Health in Pomerania Friedrich, N.
 2012
 72-73 S1 p. S58-
1 p.
 artikel
869 P01-24 The combination of the IGF-1 receptor inhibitor picropodophylin (PPP) and the BH3 mimetic ABT-737 has synergistic anti-myeloma activity Bieghs, L.
 2012
 72-73 S1 p. S40-
1 p.
 artikel
870 P02-52 The decline in pulsatile growth hormone secretion throughout early adulthood in mice is exacerbated by dietary induced weight gain Huang, L.
 2012
 72-73 S1 p. S69-
1 p.
 artikel
871 P-34 The effect of GH-IGF-I axis on renin-angiotensin system (RAS) and cardiac structure and function in patients with acromegaly Tanaka, S.
 2008
 72-73 S1 p. S37-
1 p.
 artikel
872 P-47 The effect of growth hormone (GH) and insulin-like growth factor I (IGF-I) on expression of 11β-hydroxysteroid dehydrogenase type1 (HSD1) mRNA in 3T3-L1 adipocytes Ishikawa, Y.
 2008
 72-73 S1 p. S41-
1 p.
 artikel
873 P01-42 The effect of growth hormone replacement therapy (GHRT) on exercise capacity, fat mass, ectopic lipids [intramyocellular (IMCL) and intrahepatocellular lipids (IHCL)] and insulin resistance in hypopituitary patients with growth hormone deficiency (GHD) Christ, E.
 2012
 72-73 S1 p. S47-
1 p.
 artikel
874 P94 The effects of freeze-thaw treatment and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal peptide concentrations Guha, N.
 2010
 72-73 S1 p. S74-
1 p.
 artikel
875 P84 The effects of recombinant human IGF-I/IGF-binding protein-3 on glucose homeostasis in recreational athletes Guha, N.
 2010
 72-73 S1 p. S69-S70
2 p.
 artikel
876 P62 The effects of type I IGF receptor inhibition with small-molecule diarylureas in a mouse model of type I diabetic kidney disease Troib, A.
 2010
 72-73 S1 p. S61-
1 p.
 artikel
877 P-68 The GH-IGF axis in glycogen storage disease type 1 (GSD): Evidence of different growth patterns and IGF levels in patients with GSD1 A and GSD1 B Pivonello, R.
 2008
 72-73 S1 p. S47-
1 p.
 artikel
878 P93 The growth hormone receptor exon 3 deleted/full-length polymorphism tagSNP rs6873545 is associated with obesity-related parameters in a randomly selected population Glad, C.A.M.
 2010
 72-73 S1 p. S73-S74
2 p.
 artikel
879 P97 The identification of heterozygous CUL7 sequence variants in a cohort of children born with a low birth weight Saunders, E.
 2010
 72-73 S1 p. S75-
1 p.
 artikel
880 P105 The IGF-I and IGFBP-3 response after two years of growth hormone treatment using recommended doses differs in children with growth hormone deficiency, small-for-gestational age status, Ullrich-Turner and Prader-Willi syndrome: implications for treatment? Hauffa, B.P.
 2010
 72-73 S1 p. S79-
1 p.
 artikel
881 P38 The IGF-II receptor regulates the metastatic properties of prostate cancer cells through the cross-talk with IGF-I and integrins receptors Losada-Barragán, M.
 2010
 72-73 S1 p. S53-
1 p.
 artikel
882 P-14 The IGF-1 receptor inhibitor PPP induces increased cellular uptake of glucose. Interactions between IGF-1R and insulin receptor? Vasilcanu, D.
 2008
 72-73 S1 p. S31-
1 p.
 artikel
883 P-90 The IGF system in atherosclerosis. Effect of IGFBP-1 on rat SMC proliferation in different glucose conditions Wang, J.
 2008
 72-73 S1 p. S53-
1 p.
 artikel
884 P03-4 The impact of capsaicin-induced sensory denervation on osteogenesis and mRNA expressions of IGF-1, IGF-1R and IGFBP-4 in cortical bone. A study of bone distraction in the osteotomic femur of rat Li, J.
 2012
 72-73 S1 p. S72-
1 p.
 artikel
885 P-92 The influence of glucose intake on the relative abundance of IGFBP-1 phosphoforms in the circulation Nedic, O.
 2008
 72-73 S1 p. S54-
1 p.
 artikel
886 P-25 The influences of the standardization of GH assay on the criteria for evaluating the effect of treatment of acromegaly in Japan Fukuda, I.
 2008
 72-73 S1 p. S34-
1 p.
 artikel
887 P03-27 The Insulin-like Growth Factor 1 Receptor displaces PKCs from RACK1 to facilitate migration of cancer cells Kiely, P.
 2012
 72-73 S1 p. S80-S81
2 p.
 artikel
888 P01-26 The Interactions of Insulin-like Growth Factor-I with transglutaminases – a novel pathway with wide ranging clinical implications Sivaramakrishnan, M.
 2012
 72-73 S1 p. S40-S41
2 p.
 artikel
889 P-96 The new IGF-I-responsive protein EVA promotes survival and migration signalling through regulation of endosomal pH by the V-ATPase O'Callaghan, K.M.
 2008
 72-73 S1 p. S55-
1 p.
 artikel
890 P-82 The physiological variability of insulin growth factor I and procollagen type III in amateur and elite athletes: implications in detecting growth hormone abuse in sports Erotokritou, I.
 2008
 72-73 S1 p. S51-
1 p.
 artikel
891 P-24 The Power of the Mind: an evaluation of the placebo effect in a study of GH on physical performance Meinhardt, U.
 2008
 72-73 S1 p. S34-
1 p.
 artikel
892 P-53 The pre-treatment with acylated ghrelin abolishes the GH response to GHRH and inhibits that to GHRH+ARGININE and ghrelin itself Olivetti, I.
 2008
 72-73 S1 p. S42-S43
2 p.
 artikel
893 P85 The production and regulation of insulin-like growth factor (IGF) I and II and IGF-binding proteins in human adipose tissue cultures Rasmussen, M.F.
 2010
 72-73 S1 p. S70-
1 p.
 artikel
894 P02-15 The relation between diabetic children and insulin like growth factor-1 Rasheed, A.O.
 2012
 72-73 S1 p. S54-
1 p.
 artikel
895 P-102 The relationship between central adrenal insufficiency and sleep related breathing disorders in children with Prader-Willi syndrome de Lind van Wijngaarden, R.
 2008
 72-73 S1 p. S57-
1 p.
 artikel
896 P-29 The response of plasma ACTH and AVP to growth hormone-releasing peptide-2 (GHRP-2) in healthy adults Tanimoto, K.
 2008
 72-73 S1 p. S35-S36
2 p.
 artikel
897 P01-5 The role of insulin-like growth factor binding protein-6 in the differentiation of placental mesenchymal stem cells into skeletal muscle Aboalola, D.
 2012
 72-73 S1 p. S34-
1 p.
 artikel
898 P32 The role of lipids in mammary cancer growth Alikhani, N.
 2010
 72-73 S1 p. S51-
1 p.
 artikel
899 P-108 The role of PPARgamma and IGFBP-3 in regulating breast cancer Pon, C.
 2008
 72-73 S1 p. S59-
1 p.
 artikel
900 P-06 The roles of ghrelin and obestatin in prostate cancer Amorim, L.
 2008
 72-73 S1 p. S28-
1 p.
 artikel
901 P02-16 The SOCS2 Ubiquitin ligase complex regulates Growth Hormone Receptor levels Vesterlund, M.
 2012
 72-73 S1 p. S59-
1 p.
 artikel
902 P-13 The type 1 insulin-like growth factor receptor (IGF1R) as a therapeutic target in renal cancer Wang, Y.
 2008
 72-73 S1 p. S30-S31
2 p.
 artikel
903 P01-36 The use of growth hormone and other performance enhancing drugs by university students Hayward, O.
 2012
 72-73 S1 p. S44-
1 p.
 artikel
904 P8 Thyroid function and ultrasound evaluation in patients with acromegaly Fukuda, I.
 2010
 72-73 S1 p. S41-S42
2 p.
 artikel
905 P03-8 Tumorigenicity of Ewing's sarcoma cells is dependent on the level of beta-arrestin 1 Oprea, I.I.
 2012
 72-73 S1 p. S73-S74
2 p.
 artikel
906 P4 Twelve months efficacy and safety of a novel once-a-week sustained release rhGH (LB03002): a phase III study in adults with GHD Biller, B.M.K.
 2010
 72-73 S1 p. S40-S41
2 p.
 artikel
907 P01-45 Twenty-four months efficacy and safety of LB03002, a new sustained release formulation of rhGH, in children with GHD: Extension of a phase III randomized multicentre study Saenger, P.
 2012
 72-73 S1 p. S48-
1 p.
 artikel
908 P03-1 Ubiquitin ligase Nedd4 interacts with Insulin Receptor Substrate (IRS)-2 in response to humoral/nutritional stimuli, thereby enhancing IRS-2-mediated IGF/insulin signals through a novel mechanism Fukushima, T.
 2012
 72-73 S1 p. S71-
1 p.
 artikel
909 P109 Up-regulation of IGFBP-2 following a controlled cortical impact injury Qin, M.
 2010
 72-73 S1 p. S80-S81
2 p.
 artikel
910 P-36 Using the candidate-gene approach to investigate the predictive impact of genetic polymorphisms on response to GH replacement therapy in adults Glad, C.A.M.
 2008
 72-73 S1 p. S37-S38
2 p.
 artikel
911 P54 Variations of 40 signaling proteins in two Ewing's Sarcoma xenografts following treatment with RG1507, a human IgG1 monoclonal antibody targeting IGF-1R Hofmann, M.H.
 2010
 72-73 S1 p. S58-S59
2 p.
 artikel
912 P-93 Visceral fat mass, not total fat mass or body mass index, is the strongest predictor of circulating ghrelin levels in humans Søndergaard, E.
 2008
 72-73 S1 p. S54-
1 p.
 artikel
913 P01-8 Wound healing rate is not impaired in mice with deficiency of liver-derived insulin-like growth factor-I (IGF-I) Botusan, I.R.
 2012
 72-73 S1 p. S35-
1 p.
 artikel
914 Quality of life: What is it and can it bemeasured? Strawbridge, W.J.
 1998
 72-73 S1 p. 59-62
4 p.
 artikel
915 Reduced angiogenesis and decreased COX-2 expression in colorectal neoplasia in acromegaly Bustin, S.A.
 2001
 72-73 S1 p. S136-
1 p.
 artikel
916 Reduced growth hormone response to growthhormone-releasing hormone combined with arginine in patients with the metabolic syndrome Herrmann, B.
 2001
 72-73 S1 p. S146-
1 p.
 artikel
917 Reduced retinal vascularization in children with growth hormone deficiency Hellström, A.
 1999
 72-73 S1 p. 163-
1 p.
 artikel
918 Regulation of gonadotropinmreleasing hormone release by cyclic AMP signalling pathways Weiner, Richard I.
 2001
 72-73 S1 p. S9-S15
7 p.
 artikel
919 Regulation of proliferation and apoptosis by the insulin-like growth factor I receptor Roith, Derek Le
 2000
 72-73 S1 p. S12-S13
2 p.
 artikel
920 REMOVED: P02-51 Product wastage from modern human growth hormone administration devices: A laboratory analysis Kappelgaard, A.-M.
 2012
 72-73 S1 p. S68-S69
2 p.
 artikel
921 Risk factors for short stature at 6 years of age in children of very low birthweight (< 1500 g) Takahashi, A.
 2001
 72-73 S1 p. S154-
1 p.
 artikel
922 Role, sensitivity and validity of GH stimulation tests in the diagnosis of growth hormone deficiency in adults Vierhapper, H.
 1998
 72-73 S1 p. 37-40
4 p.
 artikel
923 Scientific Program 2010
 72-73 S1 p. vii-xvi
nvt p.
 artikel
924 Scientific Program 2008
 72-73 S1 p. vii-xvi
nvt p.
 artikel
925 Signal transduction of the growthhormone (GH) receptor, and GH-binding protein Wojcik, J.
 1999
 72-73 S1 p. 51-55
5 p.
 artikel
926 Stimulation of liver growth by the tumournecrosis factor receptor 1-interleukin-6-deficient axis in mice Walienius, V.R.
 2001
 72-73 S1 p. S156-
1 p.
 artikel
927 Study of the relationship between abdominalobesity, insulin sensitivity and enzyme activity of 11β-hydroxysteroid dehydrogenase during growth hormone treatment Koranyi, J.
 2001
 72-73 S1 p. S144-
1 p.
 artikel
928 Sustained and favourable effects of 5 years of growth hormone replacement in adults on metabolic indices, body composition and muscle strength Götherström, G.
 2001
 72-73 S1 p. S128-
1 p.
 artikel
929 SY1-7: Abuse of growth hormone Strasburger, C.J.
 2014
 72-73 S1 p. S2-
1 p.
 artikel
930 SY1-3: Dosing and Monitoring GH treatment in children born SGA Léger, J.
 2014
 72-73 S1 p. S1-
1 p.
 artikel
931 SY1-2: Dosing and Monitoring GH Treatment in GH Deficient Children Cohen, P.
 2014
 72-73 S1 p. S1-
1 p.
 artikel
932 SY1-4: Dosing and monitoring GH treatment in Turner syndrome Tanaka, T.
 2014
 72-73 S1 p. S1-S2
2 p.
 artikel
933 SY1-6: Growth hormone and sarcopenia - future aspects Thorner, M.
 2014
 72-73 S1 p. S2-
1 p.
 artikel
934 SY1-5: Growth hormone replacement in adult growth hormone deficiency: long-term efficacy and safety Johannsson, G.
 2014
 72-73 S1 p. S2-
1 p.
 artikel
935 SY2-4: IGFBP-2 in Cancer: From The Matrix to The Inside Job Russo, V.C.
 2014
 72-73 S1 p. S3-
1 p.
 artikel
936 SY2-1: Insulin-like growth factor 2 mRNA binding proteins (IMP/IGF2BP) as mRNA safe houses in cancer and development Christiansen, J.
 2014
 72-73 S1 p. S2-S3
2 p.
 artikel
937 SY2-5: The G protein estrogen receptor (GPER) is involved in IGF-I/insulin signaling in cancer cells Maggiolini, M.
 2014
 72-73 S1 p. S3-S4
2 p.
 artikel
938 SY2-2: The IRS proteins: determinants of IGF-1R signaling and tumor metabolism Shaw, L.
 2014
 72-73 S1 p. S3-
1 p.
 artikel
939 Targeting the growth hormone axis as a therapeutic strategy in oncology Friend, Keith E.
 2000
 72-73 S1 p. S45-S46
2 p.
 artikel
940 Targeting the insulin-like growth factor axis in the therapy of colorectal carcinoma liver metastasis Portera Jr, Charles A.
 2000
 72-73 S1 p. S47-S48
2 p.
 artikel
941 The effect of growth hormone (GH) replacementtherapy on endothelial function and oxidative stress in patients with hypopituitarism and GH deficiency Evans, L.M.
 1999
 72-73 S1 p. 147-
1 p.
 artikel
942 The effect of long-term growth hormone (GH)treatment on muscle GH-binding protein levels and GH receptor gene expression in humans Khalfallah, Y.
 1999
 72-73 S1 p. 158-
1 p.
 artikel
943 The effect of low-dose human growth hormonereplacement therapy on insulin action in patients with adult-onset hypopituitarism McConnell, E.M.
 1999
 72-73 S1 p. 146-
1 p.
 artikel
944 The effects of growth hormone (GH) replacement therapy on lipid metabolism and carbohydrate tolerance in adults with GH deficiency Peñafiel, J.
 1999
 72-73 S1 p. 147-
1 p.
 artikel
945 The effects of growth hormone therapy on overnight metabolic fuels in patients with hypopituitarism Kousta, E.
 1999
 72-73 S1 p. 144-
1 p.
 artikel
946 The effects of short-term growth hormone and insulin-like growth factor 1 treatment on thyroid hormone concentrations in adults with primary hypothyroidism Jenkins, R.C.
 1999
 72-73 S1 p. 148-
1 p.
 artikel
947 The growth Hormone ResearchSociety consensus guidelines for the diagnosis and treatment of adult GH deficiency Hartman, M.L.
 1998
 72-73 S1 p. 25-29
5 p.
 artikel
948 The growth hormone secretagogue hexarelinimproves cardiac function in rats following experimental myocardial infarction Tivesten, Å.
 1999
 72-73 S1 p. 157-
1 p.
 artikel
949 The growth hormone secretagogue receptor Korbonits, M.
 1999
 72-73 S1 p. 93-99
7 p.
 artikel
950 The influence of an elementary diet on spontaneous growth hormone secretion in paediatric patients with Crohn's disease Böhles, H.
 2001
 72-73 S1 p. S151-
1 p.
 artikel
951 The insulin-like growth factor-binding protein superfamily Rosenfeld, Ron G.
 2000
 72-73 S1 p. S16-S17
2 p.
 artikel
952 The insulin-like growth factor (IGF)-IGF-binding protein axis in critical illness Baxter, R.C.
 1999
 72-73 S1 p. 67-69
3 p.
 artikel
953 The mechanism of arginine- and insulin-induced growth hormone release in humans Hanew, K.
 1999
 72-73 S1 p. 139-
1 p.
 artikel
954 The results of replacement therapy in patients with growth hormone deficiency Košt'álová, L.
 2001
 72-73 S1 p. S159-
1 p.
 artikel
955 The role of growth hormone and insulin-like growth factor I in the regulation of apoptosis Isgaard, J.
 1999
 72-73 S1 p. 125-128
4 p.
 artikel
956 The role of leptin and hypothalamicneuropeptides in energy homeostasis: Update on leptin in obesity Mantzoros, Christos S.
 2001
 72-73 S1 p. S85-S89
5 p.
 artikel
957 The severity of growth hormone deficiencyin adults is associated with impairment of bone status Colao, A.
 1999
 72-73 S1 p. 160-
1 p.
 artikel
958 The somatomedin hypothesis revisited in a transgenic model Isaksson, Olle
 2001
 72-73 S1 p. S49-S52
4 p.
 artikel
959 The study of cancer risks in populations Stampfer, Meir J.
 2000
 72-73 S1 p. S4-S5
2 p.
 artikel
960 The use of growth hormone (GH) secretagogues in the diagnosis of GH deficiency in humans Peino, R.
 1999
 72-73 S1 p. 101-105
5 p.
 artikel
961 Tuesday, 8 November 2016 2016
 72-73 S1 p. S15-S33
19 p.
 artikel
962 Untreated growth hormone deficiency explains premature mortality in patients with hypopituitarism Bengtsson, B.-Å.
 1998
 72-73 S1 p. 77-80
4 p.
 artikel
963 Utilization of in-patient services and prevalenceof psychiatric illness in patients with hypopituitarism and growth hormone deficiency Davies, J.S.
 1999
 72-73 S1 p. 140-141
2 p.
 artikel
964 Validation of growth hormone provocation tests in young, healthy adults Jocham, A.
 1999
 72-73 S1 p. 138-
1 p.
 artikel
965 Variability in growth hormone stimulation tests Fisker, S.
 1998
 72-73 S1 p. 31-35
5 p.
 artikel
966 Visceral obesity and the role of the somatotropic axis in the development of metabolic complications Franco, Celina
 2001
 72-73 S1 p. S97-S102
6 p.
 artikel
967 Wednesday, 9 November 2016 2016
 72-73 S1 p. S33-S34
2 p.
 artikel
                             967 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland